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SUMMARY
In experimental animals and man it has been 
postulated that antigen-induced bronchospasm is due 
to the liberation of chemical mediators from mast cells, 
and that these mediators may act either directly on 
bronchial smooth muscle or via reflex vagal pathways.
In exercise-induced asthma similar mechanisms may 
operate, possibly following non-immunological release 
of chemical mediators. The pathogenic mechanism 
underlying the increased airway reactivity to non-specific 
stimuli characteristic of asthma, and the transient 
bronchial hyper-reactivity found in some normal subjects 
is unknown, although it has been suggested that these 
responses may be due to stimulation of vagal irritant 
receptors in the bronchial epithelium.
The purpose of this study was, therefore, to 
determine the relative importance of the direct and 
reflex vagal effects of various stimuli upon bronchial 
smooth muscle. This was investigated by examining 
the effects of chemical mediators, non-specific 
stimuli and exercise upon the airways of normal 
subjects and patients with asthma.
Histamine is thought to be an important 
primary chemical mediator released from human mast 
cells, while, in some species dopamine has been 
implicated in type I hypersensitivity. The 
possible sites of action of these chemical mediators
22
upon bronchial smooth muscle were, therefore, examined. 
Firstly, the effects on airflow resistance of an 
inhaled receptor antagonist clemastine, and an 
inhaled receptor antagonist cimetidine were studied 
in normal subjects and asthmatic patients. No 
significant changes in specific conductance (sGaw) 
were seen in normal subjects. In asthmatic patients, 
however, a significant increase in forced expiratory 
volume in 1-sec (FEV^) occurred at 60, 90 and 120 
minutes following the inhalation of clemastine, 
whereas inhaled cimetidine had no bronchodilator 
effect. Clemastine and cimetidine were then tested 
on histamine-induced bronchoconstriction in normal 
subjects and asthmatic patients. Clemastine 
significantly reduced the fall in sGaw in normal 
subjects, and FEV^ in asthmatic patients, whereas 
cimetidine had no protective effect. Clemastine 
and the anticholinergic drug ipratropium bromide 
were tested on methacholine-induced bronchoconstriction 
in normal subjects. Ipratropium bromide, but not 
clemastine significantly reduced the fall in sGaw 
after methacholine. These results suggest that if 
histamine is shown to be an important mediator of 
immediate type hypersensitivity in human asthma, then 
the predominate site of action of histamine upon the 
airways is probably directly on bronchial smooth 
muscle receptors.
Specific conductance was measured before and 
after infused and/or inhaled dopamine in normal
23
subjects and patients with asthma. No significant 
changes in sGaw occurred in either group. The 
adrenergic receptor antagonist thymoxamine infused 
in combination with dopamine had no significant 
effect on sGaw in six asthmatic patients, thus 
excluding any -adrenergic activity of dopamine
masking an effect on dopamine receptors. It is 
concluded that dopamine had no acute effect on 
airflow resistance in man, and that specific dopamine 
receptors are unlikely to exist in human airways.
The effects of afferent and efferent vagal 
blockade on experimental bronchoconstriction were 
studied in normal subjects and patients with asthma. 
The anaesthetic aerosol of bupivacaine hydrochloride 
produced no significant changes in sGaw in normal 
subjects. In asthmatic patients a significant fall 
in sGaw occurred which was significantly reduced by 
prior treatment with ipratropium bromide. This 
precluded its use in further defining the afferent 
vagal component of bronchial hyperreactivity in 
asthmatic patients. Bupivacaine but not sodium 
cromoglycate or saline, abolished the cough reflex 
in both normal subjects and asthmatic patients. 
Ipratropium bromide, bupivacaine and sodium 
cromoglycate were tested on histamine-, methacholine-, 
prostaglandin and cigarette smoke-induced
bronchoconstriction in normal subjects. Half the 
normal subjects had an upper respiratory tract 
infection in the study involving histamine.
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Ipratropium bromide partially or completely reduced 
the fall in sGaw after histamine/ methacholine and 
cigarette smoke, whereas bupivacaine and sodium 
cromoglycate (methacholine and prostaglandin not
tested) had no protective effect. It is concluded 
from these studies that neither histamine, methacholine 
or cigarette smoke was acting on irritant receptors 
and a reduction in bronchoconstrictor response after 
an anticholinergic drug may not necessarily indicate 
a reflex vagal pathway. In addition, the results do 
not support the postulate that sodium cromoglycate 
reduces the activity of lung irritant receptors.
The pathogenesis of exercise-induced asthma is 
unknown, but both the release of chemical mediators 
from mast cells and reflex bronchoconstriction 
secondary to stimulation of vagal irritant receptors 
have been postulated. The ability of anticholinergic 
drugs ipratropium bromide and atropine sulphate to 
prevent exercise-induced asthma was examined in 
asthmatic patients. It was found that although 
ipratropium bromide prevented exercise-induced asthma 
in some patients, high dose atropine sulphate did not 
inhibit exercise induced asthma in the remainder.
These findings suggest that the lack of inhibition 
of exercise-induced asthma in some patients following 
anticholinergic drugs is probably not due to 
insufficient cholinergic blockade as has been previously 
suggested.
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In a further experiment the effect of ipratropium 
bromide/ sodium cromoglycate and ipratropium bromide 
plus sodium cromoglycate in the prevention of exercise- 
induced asthma was examined in patients whose main 
site of airflow obstruction was in small (classified 
non-responders) and large (classified responders) 
airways as assessed by maximal expiratory flow rate 
responses to low density gas breathing. Sodium 
cromoglycate/ ipratropium bromide and ipratropium bromide 
plus sodium cromoglycate all significantly inhibited the 
fall in FEV^ after exercise in responders. Ipratropium 
bromide had no protective effect in non-responders, 
unlike sodium cromoglycate and ipratropium bromide 
plus sodium cromoglycate. The interpretation of 
these findings in relation to the pathogenesis of 
exercise-induced asthma depends on the mode of action 
of sodium cromoglycate and ipratropium bromide. If 
sodium cromoglycate is acting by temporarily 
stabilizing the mast cell, so preventing mediator 
release, then chemical mediators may be an important 
factor in development of exercise-induced asthma in 
most extrinsic asthmatics, whereas cholinergic 
pathways may be relevant only in those patients in 
whom the main site of airflow obstruction is in the 
large central airways.
A .new oral chromone, FPL57787, which has anti­
allergic activity similar to that of sodium 
cromoglycate was found to significantly prevent
26
exercise induced asthma in asthmatic patients.
Since the principal effect of FPL57787 is thought to 
be inhibition of mast cell degranulation this result 
supports the hypothesis that exercise may provoke 
chemical mediator release. However, the receptor 
antagonist clemastine was found to have no significant 
effect in preventing exercise induced asthma. This 
latter result suggests that either the release of 
chemical mediators from mast cells is not important 
in the pathogenesis of exercise induced asthma or 
a mediator other than histamine e.g. slow reacting 
substance of anaphylaxis is of more relevance, and 
this will require further study. Finally, the H  ^
receptor antagonist cimetidine was found to 
significantly inhibit exercise induced asthma. The 
mode of action of cimetidine in this study is unknown, 
but it is suggested that it is probably not due to a 
blocking action of H^ receptors in bronchial smooth 
muscle.
In conclusion these results suggest that in normal 
subjects and some patients with asthma reflex vagal 
bronchoconstriction is probably less important in 
the bronchial response to chemical mediators, 
non-specific stimuli and exercise than the direct 
effect of these stimuli upon the airways.
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ABBREVIATIONS
The following abbreviations have been used in the text.
BTPS body temperature, pressure, and
saturated.
Cyclic AMP adenosine 3' : 5' monophosphate.
ECF-A eosinophil chemotactic factor of
anaphylaxis.
EIA exercise-induced asthma.
FEV^ forced expiratory volume in one
second.
FRC functional residual capacity.
FVC forced vital capacity.
Gaw conductance.
f
h hour.
IV intravenous.
1 , litre.
MEFV . maximal expiratory flow volume.
Min minute.
MMEF maximum mid-expiratory flow rates.
PAF platelet activating factor.
PEF peak expiratory flow.
Raw airways resistance.
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RV
SC
Sec
sGaw
SRS-A
TLC
VC
V50AIR
V50He
residual volume, 
subcutaneous. 
second.
specific conductance.
slow releasing substance of 
anaphylaxis.
total lung capacity.
vital capacity.
expiratory flows at 50% vital 
capacity breathing air.
expiratory flows at 50% vital 
capacity breathing helium.
end-expiratory thoracic gas volume.
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CHAPTER I 
HISTORICAL REVIEW
GENERAL * INTRODUCTION
The word asthma is derived directly from the Greek,
d (r e ju.oi , meaning a short drawn breath or panting.
The first clear description of an asthmatic attack is 
thought to have been made by Aretaeus the Cappadocian in 
the second century A.D. (see Adams, 1866). The modern 
concept of asthma has been attributed to the observations 
of Thomas Willis (1678) (see Major, 1948). He described 
"pneumonick" asthma which was associated with obstruction 
of the bronchi by thick humours, swelling of the walls and 
obstruction from without, while "convulsive" asthma was 
due to cramps of the moving fibres of the bronchi. In 
1717, Sir John Floyer, who himself had asthma, published 
his book A Treatise of the Asthma, in which he observed 
that- "All Violent Exercise makes the Asthmatic to breath 
short".
A concept of asthma as an abnormality of the 
nervous system was suggested by Cullen (1827), and 
thought by Salter (1868) to be frequently due to reflex 
vagal mechanisms. An alternative concept of asthma, 
as an allergic condition, was suggested by Meltzer in 
1910, based on experiments on shocked, previously 
sensitized guinea-pigs. Over fifty years later, the 
relative importance of vagal and allergic mechanisms in 
asthma is still unresolved. In an endeavour to further 
define the role of these two mechanisms in asthma, I have 
examined the effects of chemical mediators, non-specific
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stimuli and exercise upon the airways of normal subjects 
and asthmatic patients. I propose, therefore, to 
review the following topics which are relevant to this 
study: atopy and type I hypersensitivity, anatomy and
function of the airways, bronchial reactivity and 
exercise-induced asthma.
ATOPY AND TYPE I HYPERSENSITIVITY 
Atopy
A tendancy for naturally occuring sensitivity to 
environmental agents in subjects with a personal or 
family history of hay fever,, asthma and eczema was first 
noted by Cooke and Vander Veer (1916). In 1923 Coca 
and Cooke introduced the term atopy to cover allergies 
of a familial or hereditary nature. Initially it was 
thought that sensitivities were not passively 
transferable, but in 1925 Coca and Grove utilizing the 
Prausnitz Kustner test showed that this kind of response 
could be transferred by "atopic reagin" which was heat 
labile, non-precipitating, specific and long lasting. 
This was later shown to be IgE (Ishizaka, Ishizaka & 
Hornbrook, 1966) .
There has been reservation about the use of the 
term atopy (Spectors & Farr, 1976). Pepys (1975) has 
suggested that the term atopy should be used to describe 
the capacity of an individual to develop type I 
sensitivity to common allergens, as demonstrable by skin 
or serological tests, without being linked to the
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presence of clinical manifestations.
The pathogenesis of atopy is unknown. Several 
hypothesis have been proposed which include increased 
mucosal permeability, IgA deficiency, defective 
immunological control of IgE production, and 
abnormalities of the mast cell (Reeves, 1977) .
Reaqinic Antibodies
The IgE molecule is a ft  ^glycoprotein whose 
molecular weight is 190.000 and consists of two light and 
two polypeptide chains (Ishizaka, 1975). Its ability 
to gombine with basophils and mast cells resides in the 
Fc part of the molecule (Stanworth et al, 1968) . The 
sensitizing activity of human IgE is lost after heating 
while the antigen binding activity remains intact 
(Ishizaka, Ishizaka & Menzel, 1967). The concentration 
of IgE in the serum is minute, the bulk being combined 
with receptors on basophils and mast cells with high 
affinity. Elevated serum concentrations of total IgE 
in asthma were first reported by Johansson (1967). The 
more allergens the patient is allergic to, the higher 
the total IgE value (Wide, Bennich & Johansson, 1967).
The level of IgE is also raised in infections with 
helminth parasites.
In 1970 Parish described an IgG antibody to milk 
which like IgE was homocytotrophic. It differed from 
IgE, however, in that sensitization was for a very short 
time and also it was not heat sensitive. This antibody
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is now termed short-term sensitizing IgG antibody 
(IgG-STS). The clinical importance of this antibody is 
at present unknown.
Type I Hypersensitivity
The mast cell is the primary target cell in 
immediate type tissue injury (Orange, 1973). The 
structural characteristics of mast cells are the numerous 
electron dense granules each bounded by a perigranular 
membrane and the villus-like projections of the cell 
membrane (Smith, 1963). In human lung, mast cells are 
rare in the mucosa, but plentiful in the sub-mucosa where 
they are distributed randomly without any apparent 
relationship to blood vessels (Brinkman, 1968).
Bronchial lumen mast cells have also been demonstrated in 
the bronchi of rhesus monkeys, dogs (Patterson et al,
1974), and humans (Patterson et al, 1977; Ts'ao et al,
1977). In rhesus monkeys, transfer of bronchial lumen 
mast cells from animals with airway reactivity to antigen 
challenge to the bronchial lumens of animals with negative 
airways responses resulted in transient airway reactivity 
to aerosol antigen challenge (Patterson, Suszka & Harris,
1978). Patterson et al (1978) have suggested that 
respiratory lumen mast cells may be a major potential 
effector cell in IgE-mediated airway responses and also 
in infection, toxic and non-IgE-mediated immunological 
airway reactions.
Human lung and nasal polyp fragments obtained from 
allergic subjects release mediators of immediate
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hypersensitivity after being challenged with specific
antigen. Normal respiratory tissues passively
sensitized with IgE also release the same mediators after
challenge, (Austen & Orange, 1975). Mast cells are
sensitized by the attachment of IgE antibody to the cell
via the Fc region, leaving the Fab region of the antibody
sufficiently unattached to enable interaction through
specific sites with antigen (Stanworth et al, 1968) .
When IgE antibody combines with antigen a series of
events takes place leading to the liberation of chemical
mediators of immediate hypersensitivity. The primary
mediators include histamine, slow-reacting substance
of anaphylaxis (SRS-A), eosinophil chemotactic factor
of anaphylaxis (ECF-A), and platelet activating factor
(PAF). These mediators exist either preformed or are
newly generated and subsequently released following
activation of the target cell. The chemical mediators,
prostaglandin and bradykinin are considered secondary
mediators, and act as modulators of the release and/or
action of the primary mediators (Austen & Orange, 1975) .
Other mediators which may be involved in immediate type
hypersensitivity in some species are dopamine and
5-hydroxytryptamine (Assem, 1976). Dopamine has been
found in significant amounts in the lungs of ruminants
and this lung dopamine has been located in the mast cells.
It is released from isolated calf lung sensitized with
horse serum by compound 48/80 and by specific antigen,
which suggests that, at least in this species, it may be
important in immediate type allergy (Eyre & Deline, 1971) .
Serotonin (5-hydroxytryptamine) is not found in human or
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canine mast cells (Austen, 1971), although PAF might 
cause release of serotonin from platelets in allergic 
asthma which could sensitize bronchial smooth muscle 
(Hahn et al, 1978).
The possible functional inter-relationships of these 
chemical mediators are unknown. Histamine and SRS-A 
potentiate one another in bronchial smooth muscle strips 
(Brocklehurst, 1962). In vivo histamine is known to 
alter venular permeability, to constrict bronchial smooth 
muscle and to stimulate the irritant receptor (Austen & 
Orange, 1975). SRS-A in vivo contracts smooth muscle, 
enhances vascular permeability, and decreases pulmonary 
compliance (Austen & Orange, 1975). The exact functional 
properties of PAF in vivo are unknown. ECF-A, attracts 
eosinophils which contain histaminase to inactivate 
histamine, arylsulfatase B to inactivate SRS-A, and 
phospholipase D to inactivate PAF. Histamine may have 
an inhibitory effect on mediator release by elevating 
cellular adenosine 3' : 5' monophosphate (cyclic AMP) 
via an H^ receptor (Lichtenstein, 1973). It is 
unlikely, however, that the release of type I mediators 
alone can be solely responsible for subacute or chronic 
asthma.
ANATOMY AND FUNCTION OF THE AIRWAYS
General Structure
The airways consist of a series of branching tubes 
which become narrower, shorter and more numerous as they 
penetrate into the lung. The trachea branches into
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right and left main bronchi and these then subdivide into 
lobar bronchi, segmental bronchi and so on for 27 
generations. The first 19 generations make up the 
conducting airways, which contain no alveoli and 
therefore take no part in gas exchange. The terminal 
bronchioles divide into respiratory bronchioles, then 
into alveolar ducts both with alveoli budding from their 
walls. This alveolated region is known as the 
respiratory zone and is where gas exchange occurs.
Bronchial smooth muscle extends from the trachea 
down to the alveolar ducts (Widdicombe & Sterling, 1970). 
In the trachea and main bronchi there is a C shaped 
cartilaginous support and the smooth muscle is arranged 
horizontally being attached to the inner aspects of the 
cartilage. The diameter of these bronchi are reduced 
by smooth muscle contraction. In the medium and 
smaller sized bronchi, the muscular attachment to 
cartilage disappears and the direction of the fibres 
becomes more oblique; contraction reduces both the 
calibre and the length of the airways. The mass of 
muscle in proportion to the diameter of the airways 
increases in the more distal airways (Widdicombe, 1963). 
Thus smooth muscle contraction in these airways produces 
a far greater proportional decrease in the diameter of 
the smaller than larger airways (Widdicombe, 1963).
The large airways are lined by ciliated pseudo­
stratified columnar epithelium resting on a basement 
membrane. There are numerous goblet cells and the
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lamina propria consists of a small amount of reticular 
and collagenous connective tissue and many elastic fibres. 
Submucosal glands are found in airways with cartilage 
in their wall> more abundantly in the larger rather 
than the smaller bronchi. Mast cells are plentiful in 
the submucosa and have also been demonstrated in the 
bronchial lumen of rhesus monkeys, dogs (Patterson 
et al, 1974) and humans (Patterson et al/ 1977; Ts' ao 
et al, 1977).
The pulmonary arteries branch alongside the airways 
but branch more frequently than the airways. They 
supply blood to the capillary network of the terminal 
respiratory units. Supernumery pulmonary arteries 
pass into the periphery of an acinus. The bronchial 
arteries run in the airway walls supplying the 
capillary bed of the airway wall from hilum to terminal 
bronchiolus. The pulmonary veins drain all 
intrapulmonary structures and have no fixed relation 
to the airways.
Innervation of the Lung
Parasympathetic and sympathetic nerve fibres reach 
the lungs through the anterior and posterior pulmonary 
plexuses formed by branches of the vagus and the 
sympathetic. Within the lung the nerves are grouped 
in peribronchial and periarterial plexuses. The main 
motor innervation of airway smooth muscle comes from the 
vagus nerve. In both monkey and dog, dense cholinergic 
innervation has been shown using a specific histochemical
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stain acetyl cholinesterase (Fillenz, 1970; El-Bermani 
& Grant, 1975). Normal airways tone is maintained by 
vagal efferent nervous activity which can be abolished 
by anticholinergic drugs (Olsen et al, 1965) and by 
vagotomy (Widdicombe/ Kent & Nadel, 1962). Electrical 
stimulation of the vagus nerves causes broncho- 
constriction. In the absence of vagal tone, electrical 
stimulation of the thoracic sympathetic nerves has no 
significant effect on airways calibre (CabezaS/ Graf &
Nadel/ 1971). Richardson & Beland (1976) have suggested 
that no adrenergic nerves are present in human airways 
smooth muscle, although these nerves can be demonstrated 
in other species. The significance of a respiratory 
non-adrenergic inhibitory nervous system (i.e. purinergic 
nerves) remains to be established (Richardson & Bouchard,
1975) .
The current view is that respiratory reflexes 
arising from the lungs of mammals can be explained on 
the basis of three types of vagal endings: the pulmonary
stretch receptors, the irritant receptors and the type J 
receptors (Widdicombe, 1974). The sensory fibres of 
these receptors run in the vagi and enter the medulla 
oblongata. The fibres of pulmonary stretch and 
irritant receptors are myelinated, while type J 
receptors are supplied by nonmyelinated fibres in the 
cat, dog and rabbit (Widdicombe, 1974). The properties 
of these receptors have been based mainly on studies performed 
in animals. The relevance of these findings in relation to 
sensory receptor function in human airways is unknown.
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Pulmonary stretch receptors are found mainly in the 
bronchi and smaller airways. It is unclear, however, 
whether these receptors are located in the bronchial 
mucosa or smooth muscle (Paintal, 1977). The reflex 
effects produced by activation of pulmonary stretch 
receptors are thought to include inhibition of 
ventilation, relaxation of tracheobronchial smooth 
muscle, deflation reflex and Head's paradoxical reflex 
(Paintal, 1977). Irritant receptors were initially 
described by Knowlton & Larrabee (1946), and are thought 
to lie between airway epithelial cells (Fillenz & 
Widdicombe, 1972). Most of these receptors are found 
in the larynx, the bifurcation of the trachea and at 
the junction of the larger bronchi (Fillinz & Widdicombe, 
1972). The more proximal endings are thought to produce 
cough, while the main reflex effect from stimulation of 
those in the intrapulmonary airways are broncho- 
constriction and hyperpnoea (Widdicombe, 1974). There 
are species differences in the response of these 
receptors. In rabbits, excitation is produced by 
histamine, ammonia vapour and cigarette smoke (Sellick 
& Widdicombe, 1972), while canine irritant receptors, 
although sensitive to histamine, are only occasionally 
excited by ammonia and cigarette smoke (Sampson & Vidruk,
1975). The function of intrapulmonary irritant 
receptors therefore, remains contraversial, and they are 
considered by Paintal (1977) to have the same reflex 
effects as the pulmonary stretch receptors. The third 
category of receptor has been referred to in various 
terms, which include type J receptors (Paintal, 1977) and
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C-fibre endings in pulmonary and bronchial airways 
(Coleridge & Coleridge, 1977). The function of this 
receptor remains speculative and its physiological 
importance in humans is unknown.
Airway Receptors
In 1948 Ahlquist classified adrenergic receptors 
into oL and £  types. 6  -adrenergic receptors have
two distinct subtypes? /5  ^receptors are found in heart
and adipose tissue and a  2 receptors are found in blood 
vessels and other types of smooth muscle, in liver and 
skeletal muscle (Lefkowitz, 1975). Human bronchial 
smooth muscle contains predominantly /3 ^ adrenergic 
receptors, (Fleisch, Kent & Cooper, 1973) and 
stimulation of these receptors results in broncho- 
dilation (McFadden, Newton-Howes & Pride, 1970).
oi. -receptors have been reported in the smooth muscle of 
the airways of guinea pigs, rabbits, cats, old rats and 
dogs (Castro de la Mata, Penna & Aviado, 1962; Everitt 
& Cairncross, 1969? Fleisch, Maling & Brodie, 1970? 
Kneussl & Richardson, 1978). In human tracheal and 
bronchial smooth muscle, however, oJy. receptors have been 
demonstrated only in the presence of respiratory 
diseases such as bronchopneumonia and chronic obstructive 
airways disease (Kneussl & Richardson, 1978). The 
<U. receptor antagonists phenylephrine (Simonsson et al, 
1972 ^ 7  Patel & Kerr, 1973), and methoxamine (Snashall, 
Boother & Sterling, 1978) have been shown to significantly 
increase airway resistance in asthmatic subjects, while 
producing either a small effect (Anthracite, Vachon &
40
Knapp, 1971; Bianco et al, 1972) or no effect (Patel 
& Kerr, 1973; Snashall et al, 1978) in normal subjects. 
Cholinergic receptors are found in bronchial smooth 
muscle of several species (Fillenz, 1970; El-Bermani 
& Grant, 1975) and anticholinergic drugs result in 
bronchodilation (Olsen et al, 1965). Ingram et al
(1977) and Hensley et al (1978) have suggested that 
cholinergic antagonists have a greater effect on the 
more central airways and G> agonists have a greater 
effect on peripheral airways.
H^ receptors and receptors are widely 
distributed throughout the animal body, although the 
proportion of cells bearing H^ - and receptors 
varies not only with the species, but also with cell 
source (Chand & Eyre, 1975). In sheep, goats, calves, 
pigs, horses, guinea pigs and chickens, histamine 
causes contraction of tracheal and bronchial smooth 
muscle (Chand & Eyre, 1975). However, Eyre (1973) 
showed that the relaxant effect of histamine in terminal 
airway smooth muscles of sheep is mediated via H^ 
receptors, and that cat tracheal smooth muscle contains 
both H^ and H^ receptors. It is not clear whether 
both H^ and/or H  ^receptors are present in the airways 
of normal subjects and asthmatic patients, although 
in vitro experiments suggest that both H^ and H^ 
receptors occur in human bronchial smooth muscle 
(Dunlop & Smith, 1977).
Specific dopamine receptors have been identified
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in renal, mesenteric, coronary and intracerebral 
arterial vascular beds (Goldberg, 1972; Von Essen, 1972) , 
which when stimulated by dopamine cause vasodilation.
It is unknown whether such receptors exist in the human 
bronchial tree, although recently Key, Cain & Goetter
(1978) found specific dopamine receptors in canine 
bronchial smooth’muscle. There may also be receptors 
on the bronchial smooth muscle for serotonin, bradykinin, 
angiotensin II, and the prostaglandins. The function of 
these receptors is unknown, although it has been 
suggested that they may modulate airways calibre or 
may serve a purpose in utero or in the neonate (Fleisch 
et al, 1973).
BRONCHIAL REACTIVITY 
General
Patients with asthma have increased airway
reactivity to a variety of non-specific stimuli (Orehek 
(3.}et al, 1977 , which may persist.for years in the
absence of active asthma (Townley, Ryo & Kang, 1971).
This bronchial hyper-reactivity has been demonstrated
to histamine (Weiss, Robb & Blumgart, 1929; Curry, 1946),
cholinergic drugs (Curry, 1947), bradykinin (Herxheimer
& Stresemann, 1961), SRS-A (Herxheimer & Stresemann,
1963), /3 -adrenergic antagonists (McNeill 1964),
prostaglandin F^ (Mathe" et al, 1973) , dust (Dubois &
Dautrebande, 1958), cold air (Wells, Walker & Hickler,
1960), citric acid (Simonsson, Jacobs & Nadel, 1967)
and to exercise (McNeill et al, 1966). Some, but not
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all, relatives of asthmatics show increased methacholine 
reactivity, although not to the same degree as seen in 
symptomatic asthmatics (Townley et al, 1974). Transient 
bronchial hyper-reactivity has also been demonstrated in 
normal subjects after spontaneous viral infections 
(Parker, Bilbo & Reed, 1965; Empey et al, 1976?
Little et al, 1978) and after short term exposure to low 
concentrations of ozone (Golden, Nadel & Boushey, 1978) .
Bronchial reactivity is usually reproducible for a 
given patient (Spector & Farr, 1975), although responses 
may be influenced by the time of day of testing (DeVries 
et al, 1962), the overall severity of asthmatic symptoms 
(Makino, 1966? Muranaka et al, 1974? Cockcroft et al, 
1977^ ) and the baseline lung function (Makino, 1966? 
Benson, 1975? Cockcroft et a U  1977^ ). Recent 
allergen exposure (Altounyan, 1970) and acute 
respiratory infections (Parker et al, 1965? Empey 
et al, 1976) both increase reactivity. Q  2 a(^ renergic 
agonists, anticholinergic and theophylline drugs may
/ T _  \
reduce bronchial reactivity (Cockcroft et al, 1977 ),
whereas the effect of corticosteroids on bronchial 
responses is conflicting (Arkins, Schleuter & Fink,
1968? Spector & Farr, 1975).
The cause of bronchial hyper-reactivity is unknown, 
although a variety of mechanisms have been proposed:-
(1) Hypertrophy of bronchial smooth muscle
Patients with asthma may have hypertrophy and 
hyperplasia of bronchial smooth muscle (Dunnill,
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Masarella & Anderson, 1969; Houssain, 1973) which could 
contribute to the increased reactivity of the airway.
This mechanism would not account, however, for the 
decreased threshhold for cough in asthmatics (Bickerman 
& Barach, 1954) or the increased bronchial reactivity 
found in normal subjects after viral respiratory tract 
infections (Parker et al, 1965; Laitinen et al, 1976; 
Empey et al, 1976) or after exposure to ozone (Golden 
et al, 1978)
(2) Biochemical abnormalities in bronchial smooth
muscle
Szentivanyi (1968) postulated that bronchial 
hyper-reactivity in asthma resulted from an inherent 
defect in Q  adrenergic responsiveness and a relative 
increase in oi adrenergic activity. This hypothesis 
was based on experiments in normal mice sensitised with 
an' injection of Bordetella pertussis organisms which 
demonstrated a 30 to 300 fold increased sensitivity to 
histamine and a 20 to 50 fold increased sensitivity to 
serotonin. In nonimmunised mice treated with 
dichloroisoprenaline, a Q  adrenergic blocking agent, 
a similar hypersensitivity to the effects of histamine 
and serotonin developed. In support of this hypothesis, 
reduced /3  ^adrenergic metabolic and cardiovascular 
responses to sympathomimetic agents or exercise have 
been found in asthmatic patients (Cookson & Reed, 1963; 
Middleton & Finke, 1968). Human leukocytes which have 
Q 2 adrenoreceptors (Conolly & Greenacre, 1977), have been 
reported to show decreased cyclic AMP response to /3
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stimulants in asthma (Logsdon, Middleton & Coffey,
1972; Parker & Smith, 1973; Alston, Patel & Kerr,
1974; Lee, Bussee & Reed, 1977; Makino et al, 1977).
It has been suggested, however, that the diminished 
13 -adrenoceptor response in asthmatic patients may be 
due to prolonged exposure to large doses of adrenergic 
bronchodilators (Conolly & Greenacre, 1976; Morris 
et al, 1978). Further evidence against Szentivanyi1s 
hypothesis is provided by the finding that Q -adrenergic 
blockade with propranolol does not cause asthma in healthy 
subjects (Zaid & Beall, 1966; MacDonald, Ingram &
McNeill, 1967; Richardson & Sterling, 1969) . In 
some, but not all normal subjects, however, the 
bronchial response to non-specific irritants is- increased 
after /3 -adrenergic blockade (Zaid & Beall, 1966; 
MacDonald et al, 1967; Grieco & Pierson, 1971), but 
this is still less than is seen in asthmatics (Orehek,
/a j
et al, 1975 ). Normal subjects, however, develop
a progressive loss of airways responsiveness to both 
inhaled and intravenous salbutamol after regular inhaled 
salbutamol (Holgate, Baldwin & Tattersfield, 19 77) which 
does not appear to occur in asthmatic patients (Harvey 
& Tattersfield, 1978).
As well as postulating an inherent defect in /3 -
adrenergic responsiveness in asthma, Szentivanyi (1968) 
also suggested that there was a relative increase in Ji - 
adrenergic activity. oL -adrenergic receptors have 
been found in the airway smooth muscle of the guinea 
pig, rabbit, cat, rat and dog (Castro de la Mata et al,
1962; Everitt & Cairncross, 1969; Fleisch et al, 1970;
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Kneussl & Richardson, 1978). In human tracheal and 
bronchial smooth muscle obtained at autopsy, -
adrenoreceptors have been demonstrated only in the 
presence of respiratory diseases such as broncho­
pneumonia and chronic obstructive airways disease 
(Kneussl & Richardson, 1978). A significant increase 
in airway resistance in asthmatic patients after 
adrenergic stimulation has been reported with the 
<X -adrenoceptor agonists phenylephrine (Simonsson 
et al, 1972^  ; Patel & Kerr, 1973) and methoxamine 
(Snashall et al, 1978). In normal subjects, Patel 
& Kerr (1973) and Snashall et al, (1978) found no
airway response to -adrenoceptor agonists, while
small changes were reported by Anthracite et al, (1971) 
and by Bianco et al, (1972). Recently, vascular
and papillary (X -adrenergic hyper-responsiveness has 
been found in asthmatic patients (Henderson et al, 1979) .
The <X -adrenoceptor antagonist thymoxamine has 
been reported to prevent histamine, allergen and 
exercise-induced bronchoconstriction (Bianco et al, 1972; 
Gaddie et al, 1972; Patel & Kerr, 1975; Patel et al, 
1976) but has no effect on methacholine or PGF2 C><' 
induced bronchoconstriction (Patel, 1975). The 
significance of these findings is, however, unclear 
since thymoxamine, as well as having an -adrenoceptor
antagonist action, also has weak anti-histamine properties 
and may also stimulate /3 -adrenergic receptors by 
virtue of the accumulation of catecholamines from 
interference with the re-uptake mechanism. The
46
presence and possible contribution of cL -adrenergic 
hyper-responsiveness to bronchial hyper-reactivity in 
asthma, therefore, remains to be elucidated.
(3) Increase in resting bronchomotor tone
Benson (1975) has suggested that an increase in 
the resting state of the airways may contribute to 
bronchial hyper-reactivity in asthma. Two factors are 
important in relation to this hypothesis. Firstly, in 
blood vessels a similar degree of shortening narrows a 
constricted vessel more than a non-constricted vessel 
(Folkow, 1956). A similar physical relationship 
probably holds for airways, so that resistance is 
inversely related (approximately) to the fourth power 
of the radius. Experiments on dogs, in which changes 
in bronchial- calibre were measured with tantalum 
bronchograms and compared with measurements of airways 
resistance, have shown that if there is pre-existing 
airway narrowing then a small reduction in calibre 
produces a large increase in resistance (Benson &
Graf, 1977) . Secondly, resting bronchomotor tone 
may be important. Thus, drugs relaxing airway smooth 
muscle may produce a tissue unresponsive to constrictor 
influences.
In support of this hypothesis an inverse correlation
between baseline lung function and reactivity has been
found by several workers (Makino, 1966; Cockcroft et al,
1977^ ). Brown, McFadden & Ingram (1977) found that
inhaled histamine produced similar changes in residual
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volume, vital capacity and total lung capacity between 
a small group of atopic and non-atopic subjects whose 
baseline lung function was normal. Several other 
studies, however, have found no relationship between 
bronchial reactivity to methacholine, histamine or allergen 
and airways calibre in patients whose baseline lung 
function was either normal, abnormal or affected by 
inhaled bronchodilator drugs. (Cade & Pain, 1971;
Bryant & Burns, 1 9 7 6  ^  7 Fish et al, 1976; Cockcroft 
et al, 1 9 7 7 ^). Rubinfield & Pain, 1977; Cockcroft,
Ruffin & Hargreave, 1978; Mellis et al, 1978).
(4) Increased mast cell sensitivity
Bronchial lumen mast cells from rhesus monkeys with 
airway reactivity to ascaris antigen will transfer this 
reactivity to recipient animals (Patterson et al, 1978). 
These authors have proposed, therefore, that bronchial 
lumen mast cells may be the major effector cell in 
non-specific bronchial reactivity. In support of this 
hypothesis mediator release has been produced by non- 
immunological mechanisms in sensitized guinea pig and 
human lung specimens (Vane, 1971; Seale & Piper, 1978). 
Monkeys sensitized with passively transferred allergic 
serum, however, although showing responses to specific 
allergen (Paterson et al, 1965; Radermecker, Guebelle 
& Salmon, 1972), show no increase in non-specific 
reactivity to histamine (Radermecker et al, 1972).
In humans, some studies have reported finding no 
correlation between bronchial hyper-reactivity and serum
48
level of total IgE, or the number of allergens giving
positive prick test reactions (Cade & Pain, 1971?
Muranaka et al, 1974; Bryant & Burns, 1976^^; Woolcock,
(= >
Colman & Jones, 1978), although Cockcroft et al, (1977 )
found a direct association between atopic status and
the level of reactivity. Furthermore, as pointed out
(alby Bryant & Burns (1976 ), there may still be an
association between bronchial reactivity and the amount 
of IgE fixed to the bronchi, because the amount of cell 
fixed IgE bears no correlation to the serum level of 
IgE (Ishizaka, Soto & Ishizaka, 1973). This mechanism 
would not account, however, for the decreased threshhold 
for cough in asthmatics (Bickerman & Barach, 1954) or 
the increased bronchial reactivity found in normal 
subjects after viral respiratory tract infections 
(Parker et al, 1965; Laitinen et al, 1976? Empey et al,
1976).
(5) Increased sensitivity of irritant receptors
Nadel (1973) has suggested that sensitization of 
vagal irritant receptors in the airway epithelium may 
play an important role in causing bronchial hyper­
reactivity. The evidence for this hypothesis has been 
based mainly on studies in experimental animals.
Mechanical and chemical stimulation of the airways in 
animals produces bronchoconstriction which can be prevented 
by vagotomy (Nadel, 1973), thus implicating cholinergic 
vagal pathways in these responses. The chemical mediator 
histamine constricts airway smooth muscle by direct
local effect (Dale & Laidlaw, 1910), and also causes 
bronchoconstriction which is reduced by vagotomy or by 
atropine (DeKock et al, 1966; Mills & Widdicombe, 1970; 
Gold, Kessler & Yu, 1972). The same aerosol stimulates 
lung irritant receptors which are known to cause reflex 
bronchoconstriction (Mills, Sellick & Widdicombe, 1969; 
Vidruk et al, 1977). The relative strength, however, 
of direct and reflex actions of histamine on the 
airways is controversial. The findings in some studies 
have suggested that the vagus nerve plays both a 
relatively minor (Loring, Drazen & Ingram 1977; Loring 
et al, 1978; Hahn et al, 1978), and major (Gold et al, 
1972) role in the pulmonary response to aerosol histamine. 
The discrepancy between these studies may be due to 
differences in methodology (Hahn et al, 1978; Jackson 
& Richards, 1977). Loring et al, (1978) and Benson 
& Graf (1977), however, suggested that vagal efferent 
actively may modulate histamine response by producing 
a higher constant level of smooth muscle activation 
or baseline tone.
In several animal species allergen induced 
bronchoconstriction is reduced by vagotomy or by atropine 
(Mills & Widdicombe, 1970; Gold et al, 1972), and in 
rabbits allergen has been shown to stimulate lung 
irritant receptors resulting in reflex broncho­
constriction (Mills et al, 1969) . In experiments 
reported by Gold et al, (1972) allergen induced
bronchoconstriction in dogs sensitive to Ascaris suis 
could be prevented by differential afferent and efferent
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vagal blockade. Application of allergen to one lung 
caused bronchoconstriction in the opposite lung, which 
could be abolished by afferent vagal blockade of the 
lung receiving the allergen. These results suggest, 
therefore,that the parasympathetic nervous system may 
play an important role in the airway response to antigen, 
chemical mediators and non-specific stimuli in 
experimental animals.
Evidence in support of the hypothesis that reflex 
bronchoconstriction may be an important component of the 
airway changes in human asthma has been based on a number 
of factors:-
(a) The analogy between the bronchomotor mechanisms 
analysed in the experimental animal and the overall 
responses in man suggests that the same reflexes are 
involved (Widdicombe, 1975) . There are, however, some 
striking differences between species. Guinea pigs 
have different structured airways than man and the 
reaginic antibody is IgG and not IgE. Experimental 
asthma produced in dogs and monkeys is of an acute
and not a chronic form. The Hering-Breur reflex is 
strong in dogs and cats but weak in man (Widdicombe,
1961). Thus only tentative conclusions should be 
drawn between animal experiments and human asthma.
(b) Surgical denervation of the lungs in asthma The
results have been generally poorly documented although
Dimitrov-Szokodi, Husveti & Balogh (1957) reported that
surgical pulmonary denervation produced clinical
51
improvement and decreased bronchial responses to 
histamine. However, the lack of any long term 
improvement in most studies is not surprising since 
denervation can produce hyper-reactivity (Gold, 1975).
In addition, after experimental lung implantation 
both efferent and afferent vagus pathways may 
regenerate (Edmunds, Graf & Nadel, 1971).
(c) Afferent vagal nerve blockade in asthma Local 
anaesthetics have been used to inhibit afferent vagal 
sensory endings in animals (Jain et al, 1973; Dain, 
Boushey & Gold, 1975). In patients with asthma,
Petit Sc Dalhez (1970) studied the effect of inhaled 
lignocaine combined with ephedrine, although inclusion 
of ephedrine makes interpretation of their results 
difficult. More recently, Cross et al, (1976)
demonstrated that an aerosol of bupivacaine hydrochloride 
can produce reversible anaesthesia of the airways in man, 
which inhibited the cough reflex, and abolished the 
afferent pathway of a reflex induced bronchoconstriction 
in one normal subject. Using a canine model of reflex 
bronchoconstriction, Jackson & Richards (1977) suggested 
that sodium cromoglycate may reduce the activity of lung 
irritant receptors, and by this means decrease asthmatic 
attacks in man.
(d) Bronchial hyper-reactivity in human subjects Nadel, 
(1977) has suggested that the decrease in threshhold of 
irritant receptors in the airways could explain the
increased cough response to inhaled stimuli that exists 
in asthmatics (Bickerman & Barach, 1954). Viral 
respiratory tract infections cause transient damage to 
the airway epithelium (Hers & Mulder, 1961) and this 
may be a possible mechanism causing sensitization of 
irritant receptors (Nadel, 1977). Healthy human 
subjects with spontaneous viral infections (Empey et al,
1976) or with innoculations of live attenuated influenza 
virus (Laitinen et al, 1976) show exaggerated cough 
responses and histamine responses which are prevented 
and reversed by atropine sulphate. Similar hyper­
reactivity to methacholine has also been reported 
(Parker et al, 1965; Little et al, 1978). Furthermore, 
ozone which causes desquamation and degeneration of 
bronchial epithelial cells (Boatmann, Sato & Frank,
1974) produces bronchial hyper-reactivity to histamine 
which is prevented by atropine sulphate (Golden et al, 
1978) .
(e) The effect of anticholinergic drugs There is 
controversy over the clinical effectiveness of 
cholinergic blocking agents in asthma. Gold (1975) 
has suggested that the dose of atropine required to 
block antigen induced bronchoconstriction in humans is 
large (3 mg IV or 40 mg by aerosol), exceeding the dose 
needed to block normal airway tone. In animals 0.5- 
2.0 mg/Kg is required to block bronchoconstriction 
induced by electrical stimulation of the vagus 
(Widdicombe & Sterling, 1970). In addition, 
anticholinergic drugs relax bronchial smooth muscle
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which may alter its responsiveness to constrictor 
influences. These points must, therefore, be 
considered in the analysis of any experiments involving 
anticholinergic drugs.
Cholinergic blocking drugs have been reported to 
reduce the bronchoconstrictive effect of a number of 
nonantigenic stimuli in asthmatic patients including 
methacholine (Altounyan, 1964; Grieco & Pierson, 1970; 
Itkin & Anand, 1970), citric acid (Simonsson et al, 1967), 
13 -adrenergic antagonists (Grieco & Pierson, 1971), 
dusts (Simonsson et al, 1967), bradykinin (Simonsson 
et al, 1973) and cold air Simonsson et al, 1967).
Atropine sulphate at doses up to 1.2 mg and ipratropium 
bromide at doses up to 1 mg have been reported to 
prevent PGF^ oi induced bronchoconstriction (Atlanko & 
Poppius, 1975; Patel, 1975; Mathe & Hedquist, 1975; 
Orehek et al, 1 9 7 7 ^  although Newball & Lenfant (1977) 
found no reduction in the effects of very large doses 
of PGF2 oi with atropine. Inhaled atropine sulphate 
(dose range 290 jig to 5 mg) and ipratropium bromide 
(dose range 40 jig to 80 ug) have been found in most 
studies in asthmatic patients to cause a slight but 
significant reduction in the bronchoconstriction 
produced by inhaled histamine (Altounyan, 1964;
Simonsson et al, 1967; Harnett & Spector, 1976; 
Casterline, Evans & Ward, 1976; Cockcroft et al, 1 9 7 7  ^ )  
although this has not been found by other workers 
(Itkin & Anand, 1970; Woenne et al, 1978). The main 
site of action of histamine on the airways of asthmatic
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patients is, therefore, probably not via cholinergic 
pathways (Casterline et al, 1976).
The effect of anticholinergic drugs on antigen 
induced early asthmatic responses has been found to vary 
within and between different studies. In studies using 
a single antigen dose, inhaled and intravenous atropine 
sulphate and inhaled ipratropium bromide were effective 
in protecting against early asthmatic responses in eight 
out of 20 patients (Itkin & Anand, 1970), five out of 
seven patients (Yu, Galant & Gold, 1972) , seven out of 
10 patients (Orehek & Gayr.ard, 1977) and five out of 10 
patients (Ruffin, Cockcroft & Hargreave, 1978). Cockcroft 
et al, (1978) found that ipratropium bromide (dose 80 ^ ig)
produced a slight and variable reduction in the early 
asthmatic responses in 12 asthmatic patients. In studies 
using antigen dose-response curves Fish et al, (1977) and
Rosenthal et al, (1977) found anticholinergic drugs to be
ineffective. These workers suggested, however, that 
there may possibly be. a cholinergic effect of antigen 
at low doses. The reason for the apparent variation in 
effectiveness of inhaled anticholinergic drugs in 
preventing antigen induced asthma between different 
asthmatics is unexplained, but may be due to different 
techniques of antigen challenge, dose of cholinergic 
antagonists and unidentified differences between 
asthmatic patients (e.g. main site of airflow 
obstruction).
The relative importance of the parasympathetic
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nervous system in the airway response to antigen, chemical 
mediators and non-specific stimuli in humans has therefore 
not been fully resolved.
EXERCISE-INDUCED ASTHMA
For over 250 years exercise-induced asthma (EIA) 
has been recognised to occur in asthmatic patients 
(Floyer, 1717). Jones, Buston & Wharton (1962) 
demonstrated that exercise for 1-2 min duration is 
often followed by a decrease in airflow obstruction, 
but if exercise is prolonged for up to 8 min increased 
airflow obstruction, usually maximal at 5 min after 
completion of exercise, may occur. The incidence 
of clinically significant EIA in adult asthmatics 
is probably about 50% (Turner-Warwick, 1978), rising to 
over 70% in children (Silverman & Anderson, 1972) .
Several factors influence the response of asthmatic
patients to exercise. Running has been reported to be
a more potent stimulus for inducing EIA than cycling,
while swimming and walking were found to have very
little effect (Godfrey,. Silverman & Anderson, 1973) .
The specificity of exercise, however, as a provocative
factor for asthma probably depends on the relationship
of physical work load to exercising muscle mass and the
effect this has on minute ventilation (Strauss et al,
(a)1977 ; McFadden & Ingram, 1979). There is also a
direct relationship between pre-existing airway 
obstruction and the magnitude of response post-exercise 
(Haynes, Ingram & McFadden, 1976; Schachter et al, 1978).
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Recently the temperature and humidity of inspired air 
has also been shown to alter the response to exercise. 
Thus an increase in severity of EIA occurs with cold air 
breathing (Strauss et al, 1 9 7 7 ^ ;  Deal et al, 1978) and 
dry air breathing (Strauss et al/ 1978). If the 
methods used to evaluate EIA are standardized then there 
is good reproductibility between study days, and within 
the same day provided the exercises are performed at 
least 2-4 hours apart (Eggleston & Guerrant, 1976;
Haynes et al, 1976; Edmunds, Tooley & Godfrey, 1978).
The variation of a subject's response is reduced by 
selecting only those subjects with greater than 20% 
change in FEV^ and by completing studies over a short 
period of time (Eggleston & Guerrant, 1976; Haynes 
et al, 1976).
Pathogenesis
Several mechanisms have been postulated to explain 
the pathogenesis of EIA:-
(1) Hypervent ilat ion has been suggested to be an 
important factor in EIA by several workers (Crompton, 
1968; Chan-Yeung, Vyas & Grzybowski, 1971)although 
this was not confirmed by others (Silverman, Anderson 
& Walker, 1972; Allen et al, 1973; McFadden et al,
( cl)1977 ). More recently, however, it has become clear
that the sustained high minute ventilation during 
exercise, and the effect this has on inspired air 
temperature and humidity, is an important initiating 
factor in EIA (Zeballos et al, 1978; McFadden &
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Ingram, 1979).
(2) Hypocapnia as a result of hyperventilation has 
been postulated to produce airways narrowing (Herxheimer, 
1946; Fisher et al, 1970). Fisher & Hansen (1976) 
found that the inhalation of carbon dioxide relieved
EIA by an action on large and small airways. Other 
studies have failed to find any relationship between 
carbon dioxide levels and EIA (Silverman et al, 1972; 
Allen et al, 1973; McFadden et al, 1977^ ). Carbon 
dioxide may, however, exert a modulating influence 
in EIA by either reducing airflow obstruction or 
enhancing the effects of other bronchoconstrictive 
stimuli (McFadden et al, 1977^  ) .
(3) Metabolic acidosis due to hydrogen ions or lactic 
acid has been thought to induce asthma after exercise 
(Vassallo, Gee & Domm, 1972). Elevated arterial 
hydrogen ion and/or lactic acid concentrations have 
been found after exercise in asthmatic patients 
(Fisher et al, 1970; Vassallo et al, 1972; Strauss
(q)
et al, 1977 ) and these could possibly cause formation
and release of mediators of immediate hypersensitivity. 
Treatment, however, with sodium bicarbonate or sodium . 
lactate sufficient to correct the metabolic acidosis 
fails to prevent EIA (Seaton et al, 1969; Strauss
(q)
et al, 1977 ). Furthermore, the degree of
lacticacidaemia does not correlate with the severity 
of EIA (Silverman et al, 1972; Katz et al, 1971).
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(4) adrenergic blockade It has been suggested 
that the imbalance of the autonomic system in asthma 
postulated by Szentivanyi (1968) may be central to the 
pathogenesis of EIA. In some studies the. -receptor 
antagonists phentolamine, indoramin and thymoxamine 
(Gross, Souhrada & Farr, 1974? Bianco et al, 1974?
Patel et al, 1976) were reported to prevent EIA, whereas 
Sly et al, (1967) were unable to inhibit EIA in 10 
asthmatics with IV pentolamine. Unfortunately, none of 
these agents is specific for the al -receptor? 
phentolamine increases circulating catecholamine 
concentrations (Nikerson & Collier, 1970) and directly 
inhibits smooth muscle action (Taylor et al, 1965), 
indoramin and thymoxamine have receptor antagonist 
actions (Birmingham & Szolcsanyi, 1965? Alps et al, 
1972).
(5) Type I mediator release Several authors have 
suggested that exercise provokes type I mediator 
release from mast cells (Godfrey, 1975) . This 
hypothesis is based on the finding that sodium 
cromoglycate, which inhibits the release of type I 
mediators from mast cells (Orr et al, 1970), may 
prevent EIA through a similar mechanism (Davies,
1968? Godfrey & Konig, 1976? McFadden et al, 1 9 7 7  ^ ) .
Exercise may cause mediator release from sensitized
mast cells through a non-immunological mechanism
(Vane, 1971? Seale & Piper, 1978) . Neither EIA,
however, nor the protective effect of sodium
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cromoglycate correlate with total serum IgE levels 
(Fitch, Turner & Morton/ 1972; Morton, Turner &
Fitch, 1973), although serum concentrations of IgE 
may not correlate with cell fixed antibody (Ishizaka 
et al, 1973).
The primary type I mediators released from mast 
cells in vitro are histamine, SRS-A, ECF-A, and PAF; 
bradykinin and prostaglandin are considered secondary 
mediators (Austen & Orange, 1975). It has been 
suggested that /3 agonists may have both bronchodilator 
and mast cell membrane stabilizing actions (Anderson 
et al, 1976; Hetzel, Batten & Clark, 1977; Gibson 
et al, 1978; Ferris et al, 1978). Increased 
arterial plasma histamine levels have been found after 
exercise in asthmatics (Ferris, Anderson & Temple,
1978) , and the effect of receptor antagonists 
in EIA has been examined in a few patients. No 
significant protective action was found with parenteral 
mepyramine maleate (50 mg) in 5 asthmatics (McNeill 
et al, 1966) or in 2 asthmatics with oral chlorpheniramine 
(4 mg) Bianco et al, 1974). Diethylcarbamazine has 
been shown to inhibit release of SRS-A in the rat 
(Orange, Valentine & Austen, 1968) and SRS-A and 
histamine from passively sensitized monkey lung tissue 
following antigenic challenge (Ishizaka et al, 1971).
Sly & Matzen (1974) found that inhaled diethylcarbamazine 
protected against EIA in 15 out of 20 asthmatic children, 
and suggested that this supported the postulate that 
mediator release was an important mechanism in EIA.
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Corticosteroids in a single dose, either parenterally 
or by inhalation, just prior to exercise does not 
significantly prevent EIA (McNeill et al, 1966;
Konig, Jaffe & Godfrey, 1974) whereas prolonged inhaled 
betamethasone valerate may reduce EIA (Hodgson, 
McPherson, Friedman, 1974; Hartley, Charles & Seaton, 
1977). Hartley et al, (1977) postulated that prolonged 
steroids may be acting by interfering with the synthesis 
or release of mediators from mast cells. The 
prostaglandin synthetase inhibitors aspirin and 
indomethacin have no effect on EIA (Smith & Dunlop,
1975; Rudolf et al, 1975).
(6) Reflex vagal bronchoconstriction In experimental 
animals it has been postulated that allergen-induced 
bronchoconstriction is due to stimulation of irritant 
receptors in the bronchial epithelium, which elicit 
reflex vagal bronchoconstriction (Gold, 1975;
Widdicombe, 1977). A similar mechanism may occur in 
human asthma, including EIA. Circumstantial evidence 
for reflex bronchoconstriction in EIA is based on 
blocking efferent motor actions with anticholinergic 
drugs. The protective action of cholinergic blocking 
agents is, however, variable (Table I). The dose of 
atropine sulphate required in animals to block 
bronchoconstriction induced by stimulation of the vagi 
is between 0.5 mg/Kg to 2.0 mg/Kg body weight, which is 
higher than could be safely given to humans (Widdicombe 
& Stirling, 1970). Tinkelman, Cavenaugh & Cooper
61
TA
BL
E 
I 
Ef
fe
ct
 
of
 
a
n
t
i
ch
o
li
n
er
g
ic
 
dr
ug
s 
in 
pr
ev
en
ti
on
 
of
 
ex
e
rc
i
se
-
in
d
uc
e
d 
as
th
ma
 
in 
di
ff
er
en
t 
s
t
u
d
i
e
s
co
•H 
4-1 44 0 10 Li
TO 44 
O to 
rC  *H 
44 c 
04 -H  
2 E •a >a
44 * o O ' 44(J VO IT 1—1 iH CM O ' •H -HO \ \ \ \ \ \ CO C
4-1 CM o o o VO O '
44 \ \ \ \ \ \ O •HW a a a CD a a 2 a
■p
>i c
4  C  O
to o E
G -H  04 
O  44 P 
E  U  3  
<H C W 
3 3 3 
0U <44 04
E
G
O'
H2
Co
•H
4-1O
a;
4-1c
pa
44croo
i
Z
Co
•H
4JO
04
44
o
pa
4->c
(0
u
00
i-H
\ a
<N
f“4
\ ro \ \ \
O r-4 ro 00 ■ in
\ \ \ \oa oa 0Q 00 oa
H
z
c
o
•H
4-1u
to
4->
o
p
a
44
c
(0
u
H
2
C
o
•H
4->
o
to44o
pa
44c10o
u u > CJ >
a oa H oa H
to >0 TO TO to TO TO TO TO
<4J 04 0) to 04 04 (1) (1) to 04t—i i-H r-4 i-H i-H i-H i-H •-H #-H
• (0 (0 • <0 ro ro ro ro to ro
> .c .c > X .c .c .c .C .c JC
• c c • c G c G G -C c
H M H H M H H H H H M
O 'x
\o>
E o> O' O' O'ro E 2 E E O'
O \ 2• CM O' O in \
O • E • • O' O' O'1 i-H E CM i—i O' O' E E E O'
i-H 1 i-H 1 I 3 3 3o VO o VO VO O
O O
eg rH O
Oo C ca o i-H r-4 00 HI" r-4 o CM 00
> > a
W w a
a a a
> > a
i-H
> >
i-H
> a
i-H
>
rH
> >to to a a to a a a a a
a o a a a a a a a a
E E E E E
3 3 3 3 3
•H •H •H •rH •H
to <D 0) o to 0) a a (1) (D 0 a a 04 a <u
c C c c c C 0 o c G G 0 0 c o c
•H •H •H •H •H •H p p •H •rH •H p p •H p •H
a a a a a a 44 +4 a a a 44 44 a 44 a
0 o o o G 0 ro to o 0 0 to to o to o
p p p p p p p p p . p p P P p p p
44 44 -P 44 44 44 a a 44 44 44 a a 44 a 44
< < < < < < M M < < < H H < H <
>H . .
TO a a a a a a a a a a a a a a* a ’ a*
3 • • • • • • • • • • • • • • • •
44 a a a a a a Q a a a a a a D Q a
W
2
„— y— vO '.__ CM ._. in ,—* ^—v ,—,
vO „—* r~ CM VO O ' VO
VO o o> O ' rH r-~ C" ,—,
ro O ' r>- rH O ' rH O ' — O ' o> r~ r - _ _
vo i-H r— O ' rH '— 1—1 i—i rH n- CO
O ' rH - — ---' V — ._. r O ' O ' r~
i-H VO ---- • - • r - - rH •—i ON
’— * O ' ,—* rH - • c iH O ' t " • —' — rH
• iH a - to • rH (11 to •H O ' rH ----- i-H — vo • rH to to c i-H to
• to O ' rH 44 to c 44 - 0 w • •
i-H - rH 10 <0 44 to d) X 44 rH rH •
to 44 • 44 G a O ' d) to to rH
0) rH 44 c 0 c 43 c 10
44 to c O 0 c HJ to 3 c 44 44
0) rH 0 to to G E >H <0 d> 0J d) 44
rH 44 44 P CO 3 (0 P i-H (14 TO d)
fN CO •H O a (1) c •H d) <d P 1 TO 44 44
to 0 0 E .C 0 a  e rC X a c (0 3 3 rH
3 c 2 O CO E a 0) to c TO ro a P P to
44 O O rH P •H •H 0 44 •H •H O .c o O O d)
W •3 2 a u a a a a a E* 0 o 2 a a o ♦
B/
2/
6 
* 
bl
oc
ke
d 
EI
A 
in 
2 
ou
t 
of
 
6 
p
a
t
i
e
n
t
s
S.
B.
 
= 
si
ng
le
 
bl
in
d 
; 
D.
B.
 
= 
do
ub
le
 
bl
in
d 
; 
S.
C.
 
= 
su
bc
ut
an
eo
us
 
: 
I.
V.
 
= 
i
n
t
r
a
v
e
n
o
u
s
(1976) suggested that the lack of inhibition in some 
studies may be due to insufficient cholinergic blockade. 
The interpretation of studies using anticholinergic 
drugs is also complicated because these agents relax 
bronchial smooth muscle tone, which may alter its 
responsiveness to constrictor influences (Benson, 1975).
Recently McFadden & Ingram (1979) have suggested 
that airway cooling is the primary stimulus in EIA, 
and that this depends on the level of minute ventilation, 
inspirated air temperature and water content. An 
increase in severity of EIA occurs with cold 
(Strauss et al, 1 9 7 7 ^ ?  Deal et al, 1978) and dry 
air breathing (Strauss, et al, 1978). When the inspired 
air is adjusted to 38°C and 100% humidity then EIA is 
inhibited (Chen, Horton & Souhrada, 1976; Strauss 
et al, 1978). The mechanism by which cold, dry air 
potentiates EIA is unknown. Nasal breathing during 
exercise (Shturman-Ellstein et al, 1978) and local 
anaesthesia of the oropharynx (McNally, Enright & 
Souhrada, 1978) have both been reported to almost 
completely prevent EIA. These authors suggested that 
EIA is mediated through stimulation of irritant 
receptors located in the oropharynx by relatively cool, 
dry air when mouth breathing is used. The local 
anaesthetic lignocaine, however, as well as possibly 
blocking irritant receptors also has an inhibitory 
effect on mast cell release of mediators (Weiss,
Hargraves & Viswanath, 1978). Furthermore, sodium
cromoglycate has been found to have a protective effect 
on cold induced bronchospasm (Breslin & Pepys, 1975). 
Dean et al, (1978) found that vagal efferent blockade
does not prevent the potentiation of EIA produced by 
breathing cold air. They suggested that mast cells 
within the surface of the mucosa could be directly 
stimulated to release mediators of immediate 
hypersensitivity by alteration in the temperature of 
the environment as occurs in cold urticaria (Wasserman 
et al, 1977).
The mechanism of EIA may be multifactorial. In an
/T^ \
uncontrolled study reported by McFadden et al, (1977 )
the combination of sodium cromoglycate and the 
anticholinergic drug ipratropium bromide inhibited 
EIA in all patients studied, whereas ipratropium bromide 
alone inhibited only those patients with mainly large 
airways obstruction as assessed by changes in density 
dependence of maximal expiratory flow rates. Sodium 
cromoglycate was not given alone. They concluded that 
the airway response to exercise in asthmatics is 
heterogeneous in terms of predominant site of flow 
limitation and this factor appears to relate to 
mechanisms i.e. reflex vagal bronchoconstriction and 
direct airway narrowing secondary to the release of 
type I mediators from mast cells.
AIM OF THE STUDY
In allergic patients, acute bronchoconstriction 
to inhaled allergens is thought to be due to the
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liberation of chemical mediators from mast cells. 
Mediators such as histamine, slow-reacting substance of 
anaphylaxis, and in some species dopamine, have a direct 
local effect upon the airways. In addition, recent 
evidence in animals and man suggests that antigen- 
induced bronchospasm may also occur through activation 
of irritant receptors in the bronchial epithelium, which 
elicit reflex vagal bronchoconstriction (Gold, 1975; 
Widdicombe, 1977). Non-specific irritants may also 
cause bronchospasm in susceptible individuals by 
stimulation of irritant receptors. Similarly, it has 
been postulated that exercise-induced asthma may be due 
to the release of chemical mediators from mast cells 
(Godfrey, 1975), and that these mediators may act either 
directly upon bronchial smooth muscle or via reflex vagal 
pathways (Figure I). The aim of this study was, 
therefore, to define the relative importance of the 
direct and reflex vagal effects of chemical mediators, 
non-specific stimuli and exercise upon the airways of 
normal subjects and patients with asthma.
Firstly, the possible sites of action of chemical 
mediators upon bronchial smooth muscle were examined. 
Histamine is thought to be an important primary mediator 
released from human mast cells (Austen & Orange, 1975), 
while, in some species dopamine has been implicated in 
type I hypersensitivity (Eyre & Deline, 1971). Two 
types of histamine receptor (Ash & Schild, 1966; Black 
et al, 1972) and specific dopamine receptor (Goldberg, 
1972; Von Essen, 1972) have been identified in human
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tissue, and recent in vitro studies have suggested 
that and receptors and specific dopamine 
receptors are present in human and canine bronchial 
smooth muscle respectively (Dunlop & Smith, 1977;
Key, Cain & Goetter, 1978). The bronchial response 
to histamine and dopamine was studied in normal 
subjects and asthmatic patients to determine whether 
receptor, receptor and dopamine receptor 
responses were present in the airways.
\
The effects of afferent and efferent vagal 
blockade on experimental bronchoconstriction in 
normal subjects and asthmatics were then examined. 
Circumstantial evidence for reflex vagal 
bronchoconstriction in humans is based on blocking 
efferent vagal motor action by anticholinergic drugs 
(Yu et al, 1972; Empey et al, 1976). In an attempt 
to develop a more direct method of studying reflex 
vagal pathways, the effect of an anaesthetic 
aerosol of bupivacaine in blocking afferent vagal 
endings was studied.
The pathogenesis of exercise-induced asthma is 
unknown, but both the release of chemical mediators 
from mast cells (Godfrey, 1975) and reflex vagal 
bronchoconstriction secondary to stimulation of 
irritant receptors (Gold, 1975) have been postulated. 
Exercise-induced asthma is a safe and reproducable 
experimental model of acute asthma, and was, therefore, 
ideally suited for this study. It was hoped that the 
information obtained from the earlier parts of the
65
thesis could be applied to this experimental model. 
The role of chemical mediators in exercise-induced 
asthma could, therefore, be examined using drugs 
which prevent mediator release from mast cells, and 
agents which block the effect of type I mediators 
on the airways, while vagal pathways could be studied 
by blocking afferent and efferent vagal endings.
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CHAPTER II 
MATERIALS AND METHODS
HUMAN VOLUNTEERS
Normal Subjects
Fourteen male and eight female normal subjects
+ +(aged 22-37 years ; mean - ISD 26.5 - 4.6) with no 
history of chronic respiratory disease and no personal 
or family history of asthma or other atopic condition were 
studied. Nine subjects smoked 10 - 15 cigarettes per day.
Asthmatic Patients
Twenty six male and 32 female patients (aged 17-45 
+  ' +years ; mean - ISD 24.7 - 6.6) with extrinsic asthma 
and reversible airflow obstruction were studied. All 
had positive skin tests to at least one inhalant allergen 
and total serum IgE concentration about 200 U/ml.
Sodium cromoglycate and bronchodilators were discontinued 
for 12 - 24 h before each test. Patients on oral or 
aerosol corticosteroids were excluded from the study, 
as were patients who gave a history of a recent 
respiratory infection. All patients were non-smokers. 
Baseline data on individual patients is tabulated 
separately for each study.
The nature and the purpose of each study were 
explained to both patients and normal subjects. In 
those patients who were below 18 years of age informed 
consent was obtained from their parents. All 
investigations were approved by the Ethical Committee 
of this hospital and all patients and normal subjects 
gave informed consent.
67
METHODS
Body Plethysmography
The constant-volume plethysmograph (DuBois et al/ 
1956^^; DuBois, Botelho & Comroe, 1956^^) used in 
this study was manufactured by Fenyves & Gut (Basle, 
Switzerland). The chamber was fitted with a large 
window in the front wall, and a Perspex door with an 
electro-magnetic catch (Figure 2) . A calibration pump 
for the chamber was incorporated. The volume of the 
plethysmograph was 690 litres. A heated air selector 
allowed the subject to be connected either to the outside 
air, the chamber or the BTPS breathing bag. Pressure 
changes in the plethysmograph were monitored by a 
capacitive differential pressure transducer (Fenyves &
Gut, Basle) (sensitivity 0.001 - 0.2 kPa : frequency 
response linear 50H^) backed off against a rigid metal 
container (volume 50 litres) to stabilize against thermal 
drift. Pressure changes at the mouth produced by the 
inspiratory effort against the closed shutter were measured 
by a differential pressure transducer (Fenyves & Gut,
Basle) (sensitivity 0 . 5 - 5  kPa : frequency response flat 
to 50H^) backed off against the interior of the box.
Airflow was measured with a heated Fleisch pneumotachograph 
and differential pressure transducer (Fenyves & Gut,
Basle) with a linear response to 14 1/sec (frequency 
response flat to 50H^). Box and mouth pressure plus 
airflow were plotted on an X-Y recorder (Hewlett Packard, 
7041A) with a writing speed of more than 75 cm/sec and a 
linearity better than 0.2% Box Pressure, mouth pressure
and flow were calibrated before each experiment.
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FIGURE 2 CONSTANT-VOLUME PLETHYSMOGRAPH
The subject sat in the closed body plethysmograph 
and as the temperature of the air rose,a pressure 
compensation switch was periodically turned off until 
there was no further pressure drift. The subject then 
applied a nasal clip and panted shallowly through the 
pneumotachograph at approximately two cycles per second 
and at a flow rate of 0.5 1/sec. Panting was carried 
out with open glottis and with checks supported by the 
hands. On the first visit the technique of panting was 
demonstrated and the subject practiced breathing against 
the closed shutter until satisfactory recordings were 
obtained. While the subject panted the pressure 
compensation switch was turned off and changes in box 
pressure and airflow recorded on the X-Y recorder, 
followed by changes in box pressure and mouth pressure 
while the subject panted against the closed shutter which 
was automatically closed at end-expiration. This was 
then repeated oh a further four to six occasions/ the 
subject resting between each pair of recordings of 
airway resistance (Raw) and end-expiratory thoracic gas 
volume (Vtg). Thus Raw and Vtg were measured 
simultaneously at or near functional residual capacity 
(FRC). All plethysmographic measurements were carried 
out by myself, but analysis of the records of pressure 
and flow was carried out by another person (R.J.) who 
was unaware of the nature or order of agents administered. 
The results were expressed as specific conductance (sGaw), 
which is the reciprocal of airways resistance per litre 
of thoracic gas volume. The mean of four or six 
readings was taken as sGaw.
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formula:
Vtg was calculated using the following
Vtg (ml) = Kvtg | (B-47)-VKorr
Where was a standardisation factor for Vtg dependent
on range taken for box and mouth pressures, a and b 
(Figure 3) , B was barometric pressure and vKorr 
composed of the following values; apparatus deep space; 
140 ml, stomach volume with good diaphragm breathing:
170 ml (Bedell et al, 1956).
Raw was calculated using the following 
formula:
(B - 47) c
Raw = - 0.25Raw Vtg d
Where KRaw was a standardisation factor for Raw dependent 
on range taken for flow and box pressure, B was 
barometric pressure, c and d (Figure 3), and the 
constant 0.25 takes into consideration the resistance 
of the mechanical equipment between mouthpiece and 
breathing bag.
Spirometry
Spirometric recordings were measured either on a
water-sealed spirometer (Pulmotest Godart, Holland) or
a dry wedge spirometer (Vitalograph, Buckingham, England)
The water-sealed and dry wedge spirometer were calibrated
prior to each study. Forced expiratory volume in one
second (FEV^) and forced vital capacity (FVC) were
measured in triplicate with the subject always seated.
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The forced expiratory manoeuvre was explained to each 
subject prior to recording, and only those subjects in 
whom consistant readings were obtained were included in 
any of the studies. Spirometric recordings always 
followed the measurement of sGaw to avoid reflex changes 
in airways resistance (Orehek et al, 1975 ). Maximum
mid-expiratory flow rate (MMEF), which is the average 
flow rate over the middle half of the forced expiratory 
spirogram (Godart spirometer only) was also calculated.
The best recording in each case was used for analysis. 
Volumes were corrected to body temperature, pressure 
saturated with water vapour (BTPS). Predicted normal 
values were taken from Cotes (1975) and from Cherniak & 
Raber (1972) for MMEF.
Flow Volume Curves
Similar instructions to the subject and precautions 
were used in measurement of maximal expiratory flow 
volume (MEFV) curves as have been described for the 
measurement of FEV^ and FVC. The MEFV curves breathing 
air were produced using a heated Fleisch pneumotachograph 
and differential pressure transducer (Fenyves & Gut, Basle) 
with a linear response to 14 1/sec (frequency response 
flat to 50HJ) and recorded on a direct writing X-Y 
recorder (Hewlett Packard 7041A with a writing speed of 
more than 75 cm/sec and a linearity better than 0.2%) 
during forced expiration from total lung capacity (TLC) 
to residual volume (RV). No distortion of the MEFV 
curve for expiratory flows at 50% vital capacity occurred
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from the direct use of an X-Y recorder (Pollock et al, 
1977) . The MEFV curves were measured in triplicate 
with the subject seated.
After these recordings were completed, the subject 
breathed a gas mixture of 79% helium He and 21%
(He-C^) for at least one minute, which included three 
deep inspirations. The MEFV curves were measured again, 
and this was repeated on at least three occasions. The 
curves with the highest maximal flows whose vital 
capacities (VC) on air and HE-C>2 matched were used for 
analysis. The expiratory flows at 50% VC breathing air
(Vsqair) an<^  H e *-°2 ^V50He^ were measured, and the degree
of density dependence was assessed as the ratio of 
• *
VfoHe to V50AIR* Responders were those subjects in
• 0
whom the ratio Vc-„ to Vc____ was over 1.20. Volumes50He 50AIR
were corrected to BTPS. The pneumotachograph was 
calibrated for air and He-O^ prior to each study with a 
one litre pump.
Nebulisation
The inhalation of drugs was by means of a Wright 
nebuliser (Aeorsol Products (Colchester) Limited, London) 
using compressed air at a flow rate of 8 1/min by means 
of a portable air compressor (CFIB Aerolyser Electric 
Inhaler; Aerosol Products (Colchester) Limited, London). 
Throughout the experiments a separate nebuliser was 
used for each drug in order to prevent any drug 
contamination. Nebulisers were cleaned with 
"Concentrate RBS25" (Chemical Concentrates (RBBS) Limited,
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London). Each nebuliser had a capacity of approximately 
15 ml, although the volume added varied from 1 ml to 5 ml 
between different studies. The volume of drug nebulised 
was estimated from the difference in the volume of. drug 
before and after nebulisation. It was found that 
approximately 1 ml of sodium chloride (9 g/1, 0.15 mol/1) 
was nebulised each five minutes. The dose of drug 
reaching the airways was unknown, although following 
administration of drugs from pressurised aerosol 
cannisters only a small proportion (less than 10%) of the 
dose enters the small airways (Davies, 1975).
The nebuliser head was placed just outside the 
subject's open mouth during normal tidal breathing, 
with the subject seated in a draught free room.
Exercise Testing
Exercise testing consisted of steady state running on
an inclined treadmill (10°) (Walkertest motorised
treadmill, Vitalograph, Buckingham, England) for between
five and eight minutes. The treadmill was situated in a
draught free room (3.5 x 6.5 metres), the daily temperature
of which was always in the range 19 - 22°C. The speed of
the treadmill was adjusted so that the patient's pulse
rate at the end of the exercise was at least 170 - 180
beats/min. The same setting and duration was used for
each test in any one patient, and each exercise test was
performed at the same time of day, but on separate days.
In any one patient each study was completed within 10
days. The procedure for exercise testing was
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explained to each patient prior to testing. All 
patients had been shown to develop a fall of greater 
than 20% in FEV^ post-exercise in the week prior to 
being included in any exercise study.
Ten patients with extrinsic asthma were exercised 
in the manner described, following random double blind 
pre-treatment with two placebos (saline, 9 g/1, 0.15 
mol/1) 30 min prior to exercise. There was no 
significant difference (t = 0.02, P > 0.48) in the 
protective effect of pre-treatment with the two 
placebos on exercise-induced asthma (Figure 4)
(Appendix B gives details).
Drugs
Drug solutions used were ipratropium bromide 
(Boehringer Ingelheim Limited) 1 g/1, 2.4 mmol/1 and 
0.25 g/1, 0.6 mmol/1; sodium cromoglycate (Fisons 
Limited) 10 g/1, 19.5 mmol/1; prostaglandin 
(Upjohn Limited) 0.5 g/1, 1.0 mmol/1; atropine sulphate 
(Antigen Limited) 5 g/1, 7.1 mmol/1; clemastine 
hydrogen fumarate (Wander Pharmaceuticals) 1 g/1, 2.1 
mmol/1; 0.5 g/1, 1.0 mmol/1; cimetidine (Smith Kline 
& French Laboratories Limited) 100 g/1, 0.39 mol/1; 
dopamine hydrochloride (Arnar-Stone Laboratories) 0.2 g/1,
1.0 mmol/1; thymoxamine hydrochloride (W.R. Warner & 
Company Limited) 0.06 g/1, 189.0 jumol/1; dextrose 
(Travenol Laboratories Limited) 50 g/1, 0.25 mol/1; 
sodium chloride (Travenol Laboratories Limited) 9 g/1,
0.15 mol/1.
74
PLACEBO PLACEBO
1 2
10-
MAXIMUM  
% FALL in FEVj 
POST EXERCISE
20-
30-
N.S.40
FIGURE 4 EFFECT OF EXERCISE ON MAXIMUM PERCENTAGE 
FALL IN FEV1 AFTER EXERCISE (MEAN - SEM) 
FOLLOWING PLACEBO 1 OR PLACEBO 2 IN 
ASTHMATIC PATIENTS (N = 10)
Powdered bupivacaine hydrochloride (Duncan, Flockhart 
& Company Limited) was dissolved in water to make a 4% 
solution (116.6 mmol/1). A solution of citric acid 
was made up at concentrations of 200 g/1 and 100 g/1. 
Powdered histamine dihydrochloride (Sigma (London) 
Chemical Company Limited) was dissolved in water to make 
solutions at concentrations of 50 g/1, 271 mmol/1 or 
less. Powdered methacholine dihydrochloride (Sigma 
(London) Chemical Company Limited) was dissolved in 
water to make solutions at concentrations of 50 g/1,
255.0 mmol/1 or less. The solutions of histamine 
dihydrochloride and methacholine dihydrochloride were 
made up just before each experiment.
Statistical Analysis
In studies with seven or less subjects the 
statistical significance of observed changes in Raw,
Vtg and sGaw was determined using the Fisher, Irwin 
& Yates exact probability test (Siegal, 1956). In 
studies with eight or more subjects statistical 
comparisons of Raw, Vtg and sGaw were made by Wilcoxon 
matched-pairs.signed-rank test (Siegal, 1956). The 
statistical significance of observed changes in FEV^,
FVC and MMEF was determined by "Student's" paired and 
unpaired t tests. Differences were considered 
significant if P < 0.05.
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CHAPTER III
EFFECT OF ^  AND H£ RECEPTOR ANTAGONISTS ON 
AIRFLOW RESISTANCE
INTRODUCTION
Histamine is released when sensitized human lung 
tissue interacts with specific antigen in vitro 
(Austen & Orange, 1975). Evidence for histamine acting 
as a chemical mediator in asthma is based on reports of 
raised histamine levels following oral aspirin challenge 
(Stevenson et al, 1976), exercise challenge (Ferris 
et al, 1978), allergen challenge (Bhat et al, 1976) and 
spontaneously occurring asthma (Simon et al, 1977) .
In experimental animals histamine has been shown to 
constrict airway smooth muscle by a direct local effect 
(Dale & Laidlaw, 1910), and also by a reflex vagal
pathway (Gold et al, 1972). In patients with asthma,
however, histamine acts mainly by direct stimulation of 
bronchial smooth muscle (Casterline et al, 1976;
Cockcroft et al, 1978; Woenne et al, 1978). In other
tissues of the body two types of histamine receptor 
have been identified (Ash & Schild, 1966; Black 
et al, 1972). Smooth muscle contraction is mediated 
by receptors, while ^  receptor responses involve 
gastric acid secretion and cardiac stimulation. 
Vasodilation is mediated by both and (Black, Owen 
& Parsons, 1975). Recent in vitro studies have indicated 
that and receptors are present in human bronchial 
smooth muscle (Dunlop & Smith, 1977) .
The purpose of this study was to investigate 
whether and/or H  ^receptor responses are present in 
the airways of normal subjects and asthmatic patients.
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Methods
Seventeen patients with extrinsic asthma (Table II) 
and eight normal subjects (three smoked 10 - 15 
cigarettes per day) were studied. The mean of six 
recordings was calculated to give sGaw. FEV^ was 
measured in triplicate using a dry wedge spirometer 
(Vitalograph), the best recording being used for 
analysis.
All solutions were inhaled through a Wright nebuliser. 
The subject placed the nebuliser just outside the open 
mouth and took tidal breaths of the aerosol. The 
different aerosols were always inhaled by each subject 
on separate days. Subjects were unaware of the sequence 
of the aerosols which were randomly assigned. In each 
subject,tests were performed at the same time of day.
Experimental Procedures
Normal subjects:
In six normal subjects following baseline 
measurements of sGaw, saline (9 g/1, 0.15 mol/1), 
clemastine (1 g/1, 2.1 mmol/1) or cimetidine (100 g/1,
0.39 mol/1)was inhaled through a Wright nebuliser for 
5 min, sGaw then being recorded at 2, 5, 10, 20, 30 
and 60 min.
In eight normal subjects measurements of sGaw 
were performed before and 30 min after inhaling saline 
(9 g/1, 0.15 mol/1), clemastine (1 g/1, 2.1 mmol/1) 
or cimetidine (100 g/1, 0.39 mol/1) for 5 min. Five
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breaths of increasing concentrations of histamine 
dihydrochloride (1.5, 3.1, 6.2, 12.5, 25.0, 50.0 g/1, 
271mmol/l) were then inhaled every 3 min, with sGaw 
recorded at 2 min after each inhalation.
In a separate series of experiments in the same 
eight subjects, sGaw was measured before and 30 min 
after inhaling saline (9 g/1, 0.15 mol/1), clemastine 
(1 g/1, 2.1 mmol/1) or ipratropium bromide (1 g/1,
2.4 mmol/1) for 5 min. Five breaths of increasing 
concentrations of methacholine dihydrochloride (3.1, 
6.2, -12.5/ 25.0, 50.0 g/1, 255 mmol/1) were then 
inhaled every 3 min, with sGaw recorded at 2 min 
after each inhalation.
Asthmatic patients:
In eight asthmatic patients (Nos 1 - 8 )  
following baseline measurements of FEV^ saline (9 g/1, 
0.15 mol/1) or clemastine (0.5 g/1, 1.0 mmol/1) was 
inhaled for 5 min, FEV^ being recorded at 30, 60, 90 
and 120 min.
In a further eight asthmatic patients (Nos 3 - 6 ,  
8, 9, 16, 17) following baseline measurements of FEV^ 
saline (9 g/1, 0.15 mol/1) or cimetidine (100 g/1,
0.39 mol/1) was inhaled for 5 min, FEV^ then being 
recorded at 10, 30, 60, 90 and 120 min.
Finally in eight asthmatic patients (Nos 10 - 17), 
FEV^ was measured before and 30 min after inhaling 
saline (9 g/1, 0.15 mol/1), clemastine (0.5 g/1,
1.0 mmol/1) or cimetidine (100 g/1, 0.39 mol/1)
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for 5 min. Five breaths of increasing concentrations 
of histamine dihydrochloride (0.15, 0.31, 0.62, 1.25,
2.5, 5.0 g/1, 27.1 mmol/1) were then inhaled every 3 min, 
with FEV^ recorded at 2 min after each inhalation.
The statistical significance of observed changes 
in sGaw was determined using the Wilcoxon matched-pairs 
signed-rank test and Fisher, Irwin & Yates exact probability 
test (experiment involving six subjects only) and of 
observed changes in FEV^ by "Student's” paired t test. 
Differences were considered significant if P < 0.05.
RESULTS
Normal Subjects
In six subjects no significant difference was 
found in pre-treatment sGaw, or absolute changes in 
sGaw at 2, 5, 10, 20, 30 and 60 min following the 
inhalation of clemastine, cimetidine or saline (Table 
III, Figure 5) .
In eight subjects no significant difference was 
found in pre-treatment sGaw, or absolute changes in 
sGaw at 30 min following the inhalation of clemastine, 
cimetidine or saline. The change in sGaw after 
pre-treatment with clemastine was significantly smaller 
than the change in sGaw after pre-treatment with saline 
following 25.0 g/1 (P <0.05) and 50.0 g/1 (P < 0.01) 
of inhaled histamine or after pre-treatment with cimetidine 
following 25.0 g/1 (P < 0.05) and 50 g/1 (P <1 0.01) of 
inhaled histamine. After pre-treatment with cimetidine 
and saline there was no significant difference in the
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change in sGaw at each dose of inhaled histamine (P < 0.05) 
(Table IV, Figure 6). In the same eight normal subjects, 
inhaled ipratropium bromide produced a significant rise 
in sGaw (P < 0.01), whereas inhaled clemastine and 
saline had no effect on sGaw. The change in sGaw after 
pre-treatment with ipratropium bromide was significantly 
different from the change in sGaw after pre-treatment with 
clemastine or saline following 12.5, 25.0 and 50.0 g/1 
of inhaled methacholine (P < 0.01) (Table V, Figure 7).
The effects of the above agents on Raw and Vtg are 
tabulated in Appendix D, Tables XL - XLVIII.
Asthmatic Patients
In eight asthmatic patients (Nos 1 - 8 )  inhaled 
clemastine produced a significant increase in FEV^ at 
60 min (P < 0.02), 90 min (P < 0.02) and 120 min 
(P < 0.05) after the inhalation (Table VI, Figure 8).
The maximum mean % increase in FEV^ (- ISD) after 
clemastine (14.3 - 9.7) was significantly greater than 
after saline (5.7 i 3.7) (P < 0.02). In a separate 
study on eight asthmatic patients (Nos 3 - 6 ,  8, 9, 16,
17) there was no significant difference in the absolute 
change in FEV^ after pre-treatment with cimetidine or 
saline at 10, 30, 60, 90 and 120 min after the 
inhalation (Table VII, Figure 9).
In eight asthmatic patients (Nos 10 - 17) no 
significant difference was found in pre-treatment FEV^ 
or absolute changes in FEV^ at 30 min following the
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inhalation of clemastine, cimetidine or saline. After
pre-treatment with cimetidine there was no significant
difference in the change in FEV^ at each dose of inhaled
histamine when compared to after pre-treatment with saline.
The change in FEV^ after pre-treatment with clemastine
was significantly smaller than the change after
♦
pre-treatment with saline following 0.62 g/1 (P < 0.01),
1.25 g/1 (P < 0.01), 2.5 g/1 (P < 0.01) of inhaled 
histamine or after pre-treatment with cimetidine 
following 0.31 g/1 (P < 0.02), 0.62 g/1 (P < 0.05),
1.25 g/1 (P < 0.02), 2.5 g/1 (P < 0.01) of inhaled 
histamine (Table VIII, Figure 10). Because only three 
patients were able to inhale histamine at a concentration 
of 5.0 g/1 after pre-treatment with saline or cimetidine 
statistical comparison with the changes in FEV^ following 
pre-treatment with clemastine was not possible, although 
in each case the changes in FEV^ after clemastine were 
much smaller than those after saline or cimetidine.
In each of the eight asthmatic patients studied the 
cumulative log histamine dose response curve was shifted 
to the right after pre-treatment with clemastine in 
comparison to after pre-treatment with saline or 
cimetidine (Figure 11).
DISCUSSION
At least two types of histamine receptor are
involved in the histamine response (Ash & Schild, 1966) .
Clemastine is an extremely potent and specific
receptor antagonist with no central or circulatory
* #
effects in conscious animals (Romer & Weidmann, 1966).
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It possesses no significant anticholinergic or 
antiserotonin activity (Weidmann et al, 1967; Kallos,
1971). The concentration of clemastine inhaled by 
the asthmatics was half that administered to the normal 
subjects/ since a concentration of greater than 0.5 g/1 
was found to produce upper airway irritation. H  ^
receptor responses are blocked by burimamide, metiamide 
and cimetidine but not by receptor antagonists 
clemastine and chlorpheniramine (Black et al/ 1972). 
Cimetidine is a specific competitive receptor 
antagonist with no significant interaction at 
catecholamine Q  -receptors, receptors or muscarinic 
receptors (Parsons, 1977). The concentration of 
cimetidine used in this study has been shown to 
effectively inhibit ^  responses such as gastric acid 
secretion in humans (Hirschowitz, 1979).
The absence of any significant change in airways 
calibre of normal subjects after an inhaled receptor 
antagonist suggests that this receptor is not important 
in the maintenance of normal airways tone. Several 
receptor antagonists, however, have been reported to 
cause bronchodilation in asthmatic patients. Popa (1977) 
found increases in the airways calibre of 10 asthmatic 
patients after intravenously administered chlorpheniramine 
(10 mg) although this was complicated by drowsiness in 
several subjects. Nogrady et al, (1978) reported that
inhaled clemastine produced a maximum percentage increase 
in FEV^ of 21% in 12 asthmatic patients, in comparison to 
an increase of 14% found in this study. Although the
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dose and method of administration of clemastine were 
similar, the better baseline function of the patients 
in the present study may account for the smaller increase 
in FEV^ after clemastine. The reason for the difference 
in response to an inhaled antagonist between normal 
subjects and patients with asthma is unexplained but may 
indicate continuous release of histamine in the asthmatic 
group as has recently been suggested (Nogrady & Bevan,
1978).
In experimental animals, histamine acts locally on
the airway smooth muscle causing constriction (Dale &
Laidlaw, 1910) and can also stimulate vagal irritant
receptors in the airways causing reflex bronchoconstriction
(Gold et al, 1972). In normal subjects and patients
with asthma, however, the main site of action of histamine
is probably by direct stimulation of human bronchial
smooth muscle (Casterline et al, 1976; Cockcroft et al,
1978; Woenne et al, 1978; Chapter IV), via and/or
receptors. The protective action of the
receptor antagonist clemastine on histamine-induced
bronchoconstriction in asthmatic subjects confirms the
findings of Nogrady & Bevan (1978) and extends this
observation to normal subjects. These findings,
therefore, suggest that histmaine was acting at the
receptor in both normal subjects and asthmatic patients.
A similar reduction in bronchoconstrictor effect of
histamine has also been reported with less potent
(Woenne et al, 1978; Eiser, Guz & Snashall, 1978^ )
or specific (Casterline & Evans, 1977) receptor
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antagonists than clemastine. receptor antagonists
may possess to a variable degree anticholinergic and 
local anaesthetic effects (Douglas, 1975). In the 
present study, clemastine had no significant 
anticholinergic action in normal subjects and it has been 
shown to have no protective effect on methacholine 
induced bronchostriction in asthmatics (Nogrady &
Bevan, 1978). A local anaesthetic effect by clemastine 
on sensory irritant receptors is also unlikely. Firstly, 
anticholinergic drugs only slightly reduce the airway 
response to histamine in comparison to receptor 
antagonists (Casterline et al, 1976; Cockcroft et al, 
1978; Woenne et al, 1978; Chapter IV). Secondly, 
the inhaled local anaesthetic bupivacaine has no 
preventive action on histamine induced bronchoconstriction 
in normal subjects (Chapter IV). Changes in baseline 
airflow obstruction may alter bronchial reactivity 
(Benson, 1975). This is unlikely, however, to be 
relevant to the present study, since although clemastine 
causes bronchodilation in asthmatic patients, this was 
only slight at 30 min following inhaled clemastine 
when histamine challenge was performed. Furthermore, 
in normal subjects clemastine displaced the histamine 
dose response curve when there was no change in baseline 
lung function. The most likely explanation for these 
findings is that there are receptors in human 
airways.
The present results do not support the hypothesis
that receptors are present in the airways of normal
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subjects and asthmatics (Busse & Sosman, 1977). Slight 
changes in small airways function, however, could have 
been missed by measurement of specific conductance in 
normal subjects and FEV^ in asthmatic patients. Eyre 
(1973) showed that the relaxant effect of histamine on 
sheep terminal bronchus was an response. In atopic 
and non-atopic human subjects, however, inhaled histamine 
causes bronchoconstriction of both large and small 
airways (Brown et al, 1977). It is unknown whether the 
dose of cimetidine inhaled in this study was sufficient 
to produce complete receptor blockade, although a 
similar concentration of cimetidine has been shown to 
effectively inhibit other human responses 
(Hirschowitz, 1979). The inhalation technique used 
to give cimetidine and histamine should have resulted 
in a similar degree of aerosol deposition within the 
airways, even if their sites of action were different. 
There are differences between cimetidine and other 
receptor blockers in their ability to reduce mediator 
release from sensitized tissue (Drazen, Venugopalan 
& Soter, 1978). These authors found that burimamide 
and metiamide but not cimetidine increased the 
anaphylactic reactions in sensitized guinea pigs. It 
is unknown whether any possible difference between 
cimetidine and other receptor blockers would be 
relevant to the identifications of human bronchial 
smooth muscle receptors. Finally, in some 
experimental systems, antagonists have no effect 
alone, but act synergistically when combined with
antagonists (Powell & Brody, 1976). A similar 
synergistic action in bronchial smooth muscle 
cannot be excluded from this study.
If histamine is shown to be an important mediator 
of immediate type hypersensitivity in human asthma, 
then the predominant site of action of histamine is 
probably by a direct effect on bronchial smooth muscle 
receptors.
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• CHAPTER IV 
EFFECT OF DOPAMINE ON AIRFLOW RESISTANCE
INTRODUCTION
Dopamine is a naturally occurring catecholamine 
which is the immediate precursor of noradrenaline 
(Blaschko, 1957), and it has been suggested that it 
acts as an important neurotransmitter in the peripheral 
autonomic nervous system (Thorner, 1975). Dopamine 
stimulates adenosine 3' : 5' monophosphate (cyclic
AMP) synthesis in postsynaptic ganglia causing 
hyperpolarisation, which is associated with an increase 
in the threshold of excitability (Greengard, 1976).
This modulating effect of dopamine on autonomic ganglia 
could thus indirectly effect bronchial smooth muscle 
tone. Furthermore, Newman Taylor et al, (1976) 
reported an improvement in pulmonary function in patients 
with chronic asthma who were treated with the specific 
dopamine receptor agonist bromocriptine.
Specific dopamine receptors have been identified in 
renal, mesenteric, coronary and intra-cerebral arterial 
vascular beds (Goldberg, 1972; Von Essen, 1972), which 
when stimulated by dopamine cause vasodilation. It is 
unknown whether such receptors exist in the human 
bronchial tree, although recently Key et al (1978) 
reported finding specific dopamine receptors in canine 
bronchial smooth muscle. Dopamine has been found in 
significant amounts in the lung of ruminants (Von Euler 
& Lishajko, 1957), and this lung dopamine has been 
located in the mast cells (Falck, et al, 1964). Its 
release from isolated calf lung sensitized with horse 
serum by specific antigen and by compound 48/80
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suggests that, at least in this species, it may be
important in immediate type allergy (Eyre & Deline,
%
1971).
This study was undertaken to evaluate the effects 
of dopamine on airflow resistance in normal subjects 
and asthmatic patients.
METHODS
Twelve asthmatic patients with extrinsic asthma 
(Table IX) and nine normal subjects were studied. FEV^ 
was measured in triplicate on a dry wedge spirometer 
(Vitalograph) at the start of each study day, the best 
recording being used for analysis. The mean of four 
recordings was calculated to give sGaw. Radial pulse 
rate and blood pressure in supine position were 
measured 1 min before each measurement of sGaw during 
infusion studies. In each subject tests were 
performed at the same time of day.
Dopamine by Infusion
With the subject in a supine position, a "Butterfly" 
No. 19 1.1 mm needle (Abbott Ireland Limited) was 
inserted into an anticubital fossa vein and connected 
to a measured volume administration set - "Metriset" 
(AHS/UK Henleys Medical Supplies Limited).
In six normal subjects following baseline 
measurements, an infusion of dopamine (0.2 g/1, 1.0 
mmol/1) in dextrose (50 g/1, 0.25 mol/1) was commenced
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at a rate of 5 jig Kg"’^ min“  ^for 10 min. The infusion 
was then stopped and measurements made at 1, 5, 10, 15 
and 20 min. In eight asthmatic patients (Nos 1 - 8 )  
following initial measurements, a placebo infusion of 
dextrose (50 g/1, 0.25 mol/1) was commenced and after 10 
min they were disconnected from the infusion and baseline 
measurements repeated. The patients were then 
reconnected to the infusion and without the subject's 
knowledge, dopamine (0.2 g/1, 1.0 ramol/1) in dextrose 
(50 g/1, 0.25 mol/1) was substituted and infused at a 
rate of 5 jig Kg~^min""^ for 10 min. The patients were 
again disconnected from the infusion and measurements 
made at 1, 5, 10 and 20 min, dextrose (50 g/1, 0.25 
mol/1) being infused between these measurements.
Six of the asthmatic patients (Nos 3 - 8 )  were 
given an additional infusion of thymoxamine (0.06 g/1,
189.0 ^ imol/1) in dextrose (50 g/1, 0.25 mol/1) for 
10 min at a rate of 0.1 mg min"”'*' which was then 
continued in combination with dopamine (0.2 g/1, 1.0 
mmol/1) in dextrose (50 g/1, 0.25 mol/1) at a rate of 
5 jig Kg~^min”'*' for a further 10 min. sGaw was 
measured prior to each infusion and at 1 and 5 min 
after the combined infusion.
Dopamine by Inhalation
In six normal subjects following baseline
measurements, a saline solution (0.9 g/1, 0.15 mol/1)
was inhaled through a Wright nebuliser for 2 min and
sGaw recorded 1 min after the inhalation. After a
89
further 4 min dopamine (0.5 g/1, 2.6 mmol/1) was inhaled 
for 2 min and sGaw recorded 1 min later. If no change 
in airways calibre was observed the dose of dopamine 
inhaled was increased to 1 g/1 (5.2 mmol/1) and then 
to 2 g/1 (10.5 mmol/1) and sGaw measurements repeated 
at similar time intervals. A similar protocol was 
used in six asthmatic patients (Nos 2, 7, 9 - 12).
The statistical significance of observed changes 
in sGaw was determined by the Wilcoxon matched-pairs 
signed-rank test in experiments involving eight subjects 
and by the Fisher Irwin and Yates exact probability test 
in experiments involving six subjects. Differences 
were considered significant if P <0.05.
RESULTS
Bronchial Response to Dopamine by Infusion
No significant changes in sGaw were seen in normal 
subjects or in patients with asthma following the 
infusion of dopamine (Table X, Figure 12). The six 
asthmatic patients who received the combined infusion
V
of thymoxamine and dopamine showed no significant 
changes in sGaw compared to thymoxamine alone (Table 
XI, Figure 13). In both groups of subjects, pulse 
and blood pressure remained unchanged during the study 
period (Figures 14, 15). No side effects were noted 
by any subjects.
The effects of infused dopamine alone or in
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combination with thymoxamine on Raw, Vtg, radial pulse 
rate, systolic and diastolic blood pressure in normal 
subjects and asthmatic patients are tabulated in 
Appendix D, Tables XLIX - LIV.
Bronchial Response to Dopamine by Inhalation
(Table XII, Figure 16). No significant changes 
in sGaw were seen in normal subjects or asthmatic 
patients following the inhalation of dopamine.
Dopamine aerosol produced no symptoms in any of the 
subjects studied.
The effect of inhaled dopamine on Raw and Vtg 
is tabulated in Appendix D, Table LV.
DISCUSSION
The present results indicate that dopamine 
infusion at a dose that has been reported to increase 
cardiac contractility (Whitsett & Goldberg, 1972), 
cardiac output and renal blood flow (McDonald et al, 
1964), does not significantly alter airflow resistance 
in normal subjects or in patients with extrinsic asthma. 
In addition, inhaled dopamine failed to effect airflow 
resistance in a similar group of subjects. This lack 
of response in airflow resistance suggests that specific 
dopamine receptors are unlikely to exist in human 
airways, and is in keeping with the extremely weak 
peripheral (3 -adrenergic agonist action of dopamine 
found in experimental animals (McNav & Goldberg, 1966).
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It is possible, however, that specific dopamine 
receptors remained unstimulated by the dose of dopamine 
infused. It was felt unethical to give higher doses 
of infused dopamine, and this may therefore have limited 
the access of the drug to receptor sites in the lung. 
Although it is not possible to accurately estimate the 
dose of dopamine inhaled it is less likely, by this means 
of administration, that any lack of response was due to 
poor access to receptor sites on the airways. If 
dopamine is released from human mast cells, as has been 
suggested to occur in bovine lung (Eyre & Deline, 1971), 
it is unlikely to be a clinically significant factor 
in the production of airways obstruction.
In doses above 30 mg Kg” m^in""^  the predominant 
effect of infused dopamine in all vascular beds examined 
is vasoconstriction due to its action on oi. -adrenergic 
receptors (Goldberg, 1972). -adrenergic responses
have been reported in the airways of both normal subjects 
(Anthracite et al, 1971? Bianco et al, 1972) and 
asthmatic patients (Patel & Kerr, 1973? Snashall et al, 
1978). However, the dose of dopamine infused in this 
study was low and, therefore, its effect on dopamine 
receptors is unlikely to have been masked by any
oC -adrenergic activity. This was confirmed in six 
asthmatic patients by the lack of airways response to 
dopamine when it was infused in combination with the 
oI -adrenergic antagonist thymoxamine.
It is concluded that dopamine has no acute effect
92
on airflow resistance in man and that specific dopamine 
receptors are unlikely to exist in human airways.
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CHAPTER V
EFFECT OF AFFERENT AND EFFERENT VA(5AL BLOCKADE 
ON EXPERIMENTAL BRONCHOCONSTRICTION
INTRODUCTION
In experimental animals it has been postulated that 
allergen-induced bronchoconstriction is due to stimulation 
of irritant receptors in the bronchial epithelium, which 
elicit reflex vagal bronchoconstriction, and that a 
similar mechanism may occur in human asthma (Gold, 1975; 
Widdicombe, 1977). Circumstantial evidence for reflex 
bronchoconstriction in human asthma is based on blocking 
efferent vagal motor actions by anticholinergic drugs 
(Yu et al, 1972; Empey et al, 1976). Local anaesthetics 
have been used to inhibit afferent vagal sensory endings 
in animals (Jain et al, 1973; Dain et al, 1975) . In 
patients with asthma, Petit & Delhez (1970) studied the 
effect of inhaled lignocaine combined with ephedrine, 
although the inclusion of ephedrine makes interpretation 
of their results difficult. More recently, Cross 
et al (1976) demonstrated that an aerosol of bupivacaine 
hydrochloride can produce reversible anaesthesia of the 
airways in man, which inhibited the cough reflex, and 
abolished the afferent pathway of a reflex induced 
bronchoconstriction in one normal subject.
The purpose of this study was to investigate the 
effects of afferent and efferent vagal blockade on 
experimental bronchoconstriction in normal subjects and 
in patients with extrinsic asthma.
METHODS
Eight patients with extrinsic asthma (Table XIII) 
and fourteen normal subjects (seven smoked 10 - 15
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cigarettes per day) were studied. FEV^ was measured 
in triplicate on a dry wedge spirometer (Vitalograph) 
at the start of each study day, the best recording 
being used for.analysis. The mean of six recordings
Powdered bupivacaine hydrochloride was dissolved in 
water to make a 4% solution (116.6 mmol/1). This 
solution was inhaled through a Wright nebuliser for two 6 
min periods separated by 1 min. The full 12 min of 
aerosol administration was performed during normal tidal 
breathing (a deep inspiration to total lung capacity was 
also taken every 30 sec in the experiments involving the 
inhalation of cigarette smoke). Bupivacaine aerosol 
was generated at room temperature and the estimated 
dose nebulised was 100 mg (291.5 ^ imol/1). Experiments 
were performed within 10 min of inhaling bupivacaine 
aerosol. Ipratropium bromide (1 g/1, 2.4 mmol/1) 
and sodium cromoglycate (10 g/1, 19.5 mmol/1) were 
also administered via a Wright nebuliser for 12 min.
The estimated dose of ipratropium bromide nebulised 
was 2.0 mg (4.8 , and that of sodium cromoglycate
after inhaling ipratropium bromide and sodium 
cromoglycate. Control aerosols of sodium chloride 
(9 g/1, 0.15 mol/1) were administered in exactly 
the same manner as the active drugs. Pre-treatments 
were randomly assigned.
was calculated to give sGaw. In each subject, tests
were performed at the same time of day.
20 mg Studies were carried out 30 min
Experimental Procedures
Cough reflex. This was tested in six normal and
four asthmatic patients using a solution of citric acid 
at concentrations of 200 g/1 and 100 g/1 respectively 
from a Wright nebuliser/ with a control solution of 
saline, the subject being unaware of which solution was 
to be administered. A cough was recorded as being 
either present or absent after one to a maximum of five 
normal inspirations as described by Bickerman & Barach 
(1954). The cough reflex was tested in both normal 
subjects and asthmatics after the administration of 
either bupivacaine, sodium cromoglycate or saline.
Bronchial response to bupivacaine. In five normal 
subjects following baseline measurements of sGaw before 
and after saline, bupivacaine or saline was inhaled 
through a Wright nebuliser for two 6 min periods 
separated by 1 min, sGaw then being recorded at 1, 5, 
10, 15 and 20 min. A similar protocol was used in 
five asthmatics, except that bupivacaine was nebulised 
for only 6 min and ipratropium bromide was inhaled 
prior to bupivacaine.
Bronchial response to methacholine. In five normal
subjects following baseline measurements of sGaw, 
methacholine dihydrochloride (10 g/1, 51.0 mmol/1) was 
inhaled through a Wright nebuliser for 2 min, with 
sGaw then recorded at 1, 5 and 10 min. Bupivacaine, 
ipratropium bromide or saline was inhaled separately 
prior to methacholine. In six asthmatics ipratropium
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bromide or saline was each administered separately prior 
to methacholine (1 g/1, 5.1 mmol/1).
Bronchial response to histamine. Histamine 
dihydrochloride (5 g/1, 27.1 mmol/1) and (2 g/1, 10.8 
mmol/1) was given in a similar manner to methacholine 
to six normal subjects, three of whom had an upper 
respiratory tract infection. Bupivacaine, ipratropium 
bromide, sodium cromoglycate or saline was each given 
separately prior to histamine (5 g/1, 27.1 mmol/1).
Bronchial response to prostaglandin . Prostaglandin
(PG) 0^ (0.5 g/1, 1.0 mmol/1) was administered in a
similar manner to methacholine and histamine to five 
normal subjects following either bupivacaine, ipratropium 
bromide or saline. sGaw was recorded at 1 and 5 min.
Bronchial response to cigarette smoke. In eight normal 
subjects (seven of whom were regular smokers) following 
baseline measurements of sGaw, cigarette smoke was 
inhaled every 30 sec for 5 min from a medium tar filter­
tipped cigarette, with sGaw then recorded at 2 min. 
Bupivacaine, ipratropium bromide, sodium cromoglycate 
or saline was each administered separately prior to the 
inhalation of cigarette smoke. All subjects abstained 
from smoking for a minimum of 2 hr prior to testing.
Statistical comparisons were made by the Fisher,
Irwin & Yates exact probability test and Wilcoxon
match-pairs signed-rank test (experiment involving
eight subjects only). Differences were considered
significant if P < 0.05.
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RESULTS
Cough reflex (Table XIV)
An aerosol of citric acid (200 g/1) produced a 
cough in six normal subjects after one to four 
inhalations. No cough reflex was produced after 
saline aerosol. Bupivacaine aerosol prevented the 
cough reflex in all subjects/ even with five inhalations 
of citric acid. Sodium cromoglycate had no preventive 
action on the cough reflex, and in each subject the 
number of inhalations of citric acid required to produce 
cough was identical to the control experiment.
In asthmatic patients a cough reflex was elicited 
after one to four inhalations of an aerosol of citric 
acid (100 g/1). Although bupivacaine produced 
bronchoconstriction it prevented the cough reflex 
even with five inhalations, whereas sodium 
cromoglycate had no preventive action. In both 
normal subjects and asthmatics the cough produced by 
citric acid was accompanied by a slight raw sensation 
in the throat and anterior upper chest. This 
sensation was only prevented by pre-treatment with 
bupivacaine.
Bronchial response to bupivacaine
All subjects noted that bupivacaine aerosol 
tasted bitter particularly during the first few min 
of inhalation and was associated with a cough in some 
subjects. Bupivacaine had no significant effect on
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sGaw in normal subjects (Table XV) but produced a 
significant bronchoconstriction at 1, 5, 10 and 20 
min in the asthmatic patients (Table XVI, Figure 17). 
This fall in sGaw was significantly reduced (P < 0.05) 
by pre-treatment with ipratropium bromide.
Bronchial response to methacholine (Tables XVII,
XVIII? Figure 18)
Methacholine aerosol produced slight throat 
irritation associated with an occasional cough in normal 
subjects. These sensations were abolished by 
pre-treatment with bupivacaine. Ipratropium bromide 
significantly prevented the fall in sGaw due to 
methacholine (P < 0.05) whereas bupivacaine had no 
protective effect. In six asthmatic patients, 
ipratropium bromide prevented the changes in sGaw 
due to methacholine.
Bronchial response to histamine (Table XIX, Figure 19)
Histamine aerosol produced slight throat irritation, 
occasional cough and mild retrosternal tightness in 
most normal subjects. The change in sGaw due to 
histamine was partially reduced by ipratropium bromide 
at 1 min, but not at 5 or 10 min, while bupivacaine and 
sodium cromoglycate had no preventive effect.
Bupivacaine abolished the sensations associated with 
histamine inhalation. The three subjects who had an 
upper respiratory tract infection showed similar 
changes in sGaw due to histamine as the other normal 
subjects. The effect of pre-treatment with ipratropium
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bromide, bupivacaine or sodium cromoglycate on histamine 
induced bronchoconstriction did not differ between the 
two groups.
Bronchial response to prostaglandin F (Table XX,
Figure 20)
Normal subjects experienced initial coughing, 
retrosternal tightness and produced small amounts of 
watery sputum. Bupivacaine prevented the initial 
cough and retrosternal tightness, but had no effect 
on the watery sputum, which was prevented by ipratropium 
bromide. Neither ipratropium bromide or bupivacaine 
prevented the changes in sGaw in the normal subjects.
Bronchial response to cigarette smoke (Table XXI,
Figure 21)
Ipratropium bromide significantly prevented the 
fall in sGaw due to cigarette smoke (P < 0.05), whereas 
bupivacaine or sodium cromoglycate had no protective 
effect.
The effects of the above agents on Raw and Vtg are 
tabulated in Appendix D, Tables LVI - LXIV.
DISCUSSION
In experimental animals cough receptors are 
concentrated especially in the larynx and tracheal 
bifurcation, whereas irritant receptors are found 
within the lung to the level of the bronchioles 
(Fillenz & Widdicombe, 1972). The more proximal
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cough receptors are, therefore, likely to be exposed 
to greater quantities of aerosol than the more distal 
irritant receptors. In the present study a 4% 
bupivacaine solution was given for 12 min at room 
temperature without any significant side effects in 
normal subjects. The total dose of bupivacaine 
delivered to the airways by this method was similar 
to that of Cross et al, (1976) who used a heated 
aerosol of bupivacaine. Although bupivacaine aerosol 
administered by the method described here could abolish 
the cough reflex in both normal and asthmatic patients, 
it is unknown whether complete irritant receptor 
blockade was achieved. The inhalation technique used 
to give pharmacological blocking and bronchoconstricting 
aerosols was, however, the same, so that in any one 
subject the deposition of aerosols within the airways 
should have been similar, even if the sites of action 
were different. In addition, the pharmacological 
blocking drugs were inhaled for six times the duration 
of the bronchoconstricting agents.
Bupivacaine aerosol had no effect on airways 
conductance in normal subjects, as reported by Cross 
et al, (1976), who found that two patients with
bronchial asthma developed severe asthma after 
bupivacaine aerosol. The present results extend this 
observation in asthmatics and so confirm the 
bronchoconstriction effect of bupivacaine. This 
precluded its use for further study with other 
bronchoconstrictor agents in asthmatic patients. The
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reason for the bronchial hyper-reactivity to bupivacaine 
and the partial reduction of this by ipratropium bromide 
is unknown. Although the inhalation of irritant 
aerosols may increase laryngeal resistance (Stransky, 
Szereda-Przestaszewaka & Widdicombe, 1973? Szereda- 
Przestaszewaka, 1974), this is unlikely to have altered 
sGaw when measured, as in this study, at a flow rate of 
0.5 1/s with the larynx held open. Furthermore, 
laryngeal resistance would be resistant to an 
anticholinergic drug, since the intrinsic laryngeal 
muscles are striated. The inhibitory action of 
ipratropium bromide, at a dose sufficient to prevent 
methacholine induced bronchoconstriction, suggests that 
bupivacaine might be partially acting via a vagal 
pathway. Alternatively, the bronchodilation from 
ipratropium bromide might result in reduced bronchial 
reactivity, due to a change in baseline airflow 
obstruction (Benson, 1975), although the difference 
between baseline values after saline or ipratropium 
bromide was small. The sites of action of bupivacaine 
on the airways appears to be on the afferent vagal 
receptors (Jain et al, 1973? Dain et al, 1975) and 
probably also on the post ganglionic parasympathetic 
motor fibres in the muscular layer of the airway wall 
(Dain et al, 1975). Methacholine acts on the smooth 
muscle cholinergic receptor, and probably has no direct 
effect on irritant receptors (Vidruk et al, 1977). It 
seems likely, therefore, that bupivacaine has no 
blocking action on the smooth muscle cholinergic
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receptors, since in normal subjects the bronchial 
response to methacholine was prevented by ipratropium 
bromide but not by bupivacaine.
Sodium cromoglycate is thought to act by 
temporarily stabilising the mast cell and so preventing 
mediator release (Orr et al, 1970). More recently, 
using a canine model of reflex bronchoconstriction, 
Jackson & Richards (1977) suggested that sodium 
cromoglycate may also reduce the activity of lung 
irritant receptors, and by this means reduce asthmatic 
attacks in man. In the present study, however, sodium 
cromoglycate given at the normal therapeutic dose of 20 
mg did not inhibit the cough reflex in either normal 
subjects or asthmatic patients. The bronchoconstrictor 
effects of cigarette smoke and histamine, which have 
been postulated to have reflex vagal actions (Nadel & 
Comroe, 1961; Empey et al, 1976) were also not inhibited 
by sodium cromoglycate in normal subjects. In addition, 
sodium cromoglycate has been shown to be ineffective in 
preventing the bronchoconstrictor response to histamine 
(Kang et al, 1976? Cockcroft et al, 1 9 7 7  ^ )  j_n 
asthmatics.
If the dose and method of administration of 
bupivacaine was sufficient.to block irritant receptors, 
then the present results indicate that histamine was not 
acting on these receptors. The partial inhibition of 
histamine-induced bronchoconstriction by an 
anticholinergic drug does, however, suggest that vagal
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pathways may be involved. Alternatively, ipratropium 
bromide could have left the airway smooth muscle fully 
relaxed and less responsive to constrictor influences, 
although the mean baseline value of sGaw after 
ipratropium bromide or bupivacaine was similar. Upper 
respiratory tract infections in healthy human subjects 
produces transient bronchial hyper-reactivity to inhaled 
histamine, which can be inhibited by atropine (Empey 
et al,1976). These authors suggested that vagal 
sensory receptors are sensitized by viral respiratory 
infection which when stimulated by histamine produce 
reflex vagal bronchoconstriction. The vagal component 
of this bronchial hyper-reactivity to histamine may, 
however, comprise predominantly efferent vagal 
hypersensitivity. In support of this, increased 
response to methacholine has been reported in normal 
subjects with an acute respiratory tract infection 
(Parker et al, 1965). The effect of histamine on 
normal airways is only partially prevented by 
ipratropium bromide, suggesting that the main site of 
action of histamine is probably directly on bronchial 
smooth muscle via receptors (Chapter III).
There is a marked and unexplained difference in the 
sensitivity of asthmatic and normal subjects to inhaled 
PGF2 d, (Mathe et al, 1973). The failure of ipratropium 
bromide or bupivacaine to significantly prevent PGF2 oi, 
induced bronchoconstriction in normal subjects is in 
agreement with previous reports using atropine (Mathe" & 
Hedqvist, 1975; Smith, Cuthbert & Dunlop, 1975; Newball
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& Lenfant, 1977), and indicates that Pr°kably
acting directly on bronchial smooth muscle rather than 
by vagal pathways.
Reflex vagal bronchoconstriction secondary to 
stimulation of irritant receptors by inhaled cigarette 
smoke occurs in rabbits (Sellick & Widdicombe, 1971), 
but only to a minor degree in dogs (Sampson & Vidruk,
1975). It has been suggested that cigarette smoke 
may act on irritant receptors in humans (Nadel &
Comroe, 1961) and this is supported by the finding that 
anticholinergic drugs block this response (Sterling, 1967; 
Gayrard, Orehek & Charpin, 1975). Despite the marked 
variability of bronchial responses to smoking (Clarke 
et al, 1970) the present results suggest that inhaled 
cigarette smoke was not acting on these receptors.
Since cigarette smoke acts predominately on the 
larger central airways (DaSilva & Hamosh, 1973;
Costello et al, 1975) it is unlikely that insufficient 
irritant receptor blockade by bupivacaine could explain 
these findings. The reason for the bronchial reactivity 
to cigarette smoke in normal subjects remains unexplained, 
but both the particulate and vapour phase of smoke appear 
to be involved (Clarke et al, 1970).
Increased irritant receptor sensitivity has been
postulated to be the cause of the exaggerated airway
reactivity characteristic of asthma (Nadel, 1977;
Widdicombe, 1977). Experimental support for this in
man has been based mainly on blocking efferent vagal
motor actions of anticholinergic drugs. However, in
105
normal subjects the present results suggest that a 
reduction in bronchoconstrictor response following an 
anticholinergic drug may not necessarily indicate a 
reflex vagal pathway. Unfortunately, the 
bronchoconstricting action of bupivacaine precluded 
its use in further defining the vagal component of 
bronchial hyper-reactivity in asthmatic patients.
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FIGURE 17 EFFECT OF INHALED BUPIVACAINE ON sGAW 
IN ASTHMATIC PATIENTS (N = 5)
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FIGURE 20 EFFECT OF INHALED PROSTAGLANDIN F2 
ON sGaw FOLLOWING IPRATROPIUM, 
BUPIVACAINE OR SALINE IN NORMAL 
SUBJECTS (N = 5)
TABLE XXI Effect of Inhaled cigarette smoke on sGaw following Ipratropium, bupivacaine. sodium cromoqlycate or saline 
In normal subjects (N=8)
Subject
Age
Basel:
(s-J
Lne sGaw 
[kPa_1)
Change in sGaw after cigarette smoke
Sex Pre-treatment B A 2 min
RJ 23 F Saline 2.14 2.21 -0.53
KR 28 F 1.80 2.01 -0.25
MS 27 F 3.41 3.89 -1.12
AL 24 F 2.89 2.83 -1.04
WF 27 F 1.93 2.08 -0.68
YI 23 F 0.87 1.02 -0.16
LF 22 F 1.04 1.05 -0.10
IW 37 M 1.06 1.06 -0.28
Mean
SEM
1.89
0.32
2.01
0.35
-0.52
0.13
RJ Sodium Cromoglycate 3.06 3.50 -1.13
KR 2.51 2.71 -0.79
MS 3.44 3.61 -0.91
AL ' 2.30 2.59 -1.07
WF 2.16 1.40 -0.33
YI 1.00 1.30 -0.03
LF 1.47 1.07 -0.29
IW 1.18 1.21 -0.16
Mean
SEM
2.13
0.31
2.17
0.37
-0.58
0.15
RJ Ipratropium 3.49 4.07 +0.17
KR 1.86 3.18 -0.06
MS 3.17 5.42 +0.22
AL 2.48 3.70 -0.28
WF 1.28 1.62 -0.08
YI 0.88 1.13 -0.25
LF 1.38 2.00 +0.66
IW 1.21 1.27 -0.00
Mean 1.96 2.80 -0.04*
SEM 0.34 0.54 0.10
RJ Bupivacaine 2.92 2.38 -0.57
KR - 2.20 1.81 -0.15
MS 3.50 3.45 -0.91
AL 2.50 2.50 -0.64
WF 1.49 1.38 -0.22
YI 1.01 1.03 -0.26
LF 1.13 0.81 -0.10
IW 0.91 0.96 -0.04
Mean 1.95 1.79 -0.36
SEM 0.34 0.32 0.10
B, before pre-treatment; A, after saline, sodium cromoglycate, ipratropium or bupivacaine
* Values significantly different from those with saline pre-treatment (p <  0.05)
ABSOLUTE CHANGES
in sGaw(S-1 KPa-1)
+0-8-
+0-6-
+0-4-
+0-2-
0-
-0-2-
-0 -4 -
-0-6-
-0-8
D ifference in 
P re-cigarette  
Smoke  
Baseline 
Values
Pretreatm ent 
■ Ipratropium  
•  Bupivacaine  
▲ Sodium  C rom oglycate  
o Saline
*  p < 0 - 0 5
CIGARETTE  
S M O K E
T IM E  (m in)
FIGURE 21 EFFECT OF INHALED CIGARETTE SMOKE ON
sGaw FOLLOWING IPRATROPIUM, BUPIVACAINE, 
SODIUM CROMOGLYCATE OR SALINE IN NORMAL 
SUBJECTS (N = 8)
CHAPTER VI
EFFECT OF INHALED HIGH DOSE 
ANTICHOLINERGIC DRUGS IN PREVENTION OF
EXERCISE-INDUCED ASTHMA
INTRODUCTION
Exercise-induced asthma (EIA) may be due to reflex 
vagal bronchoconstriction. secondary to stimulation of 
irritant receptors. Circumstantial evidence for reflex 
bronchoconstriction occurring in EIA is based on blocking 
efferent motor actions by anticholinergic drugs. The 
protective action of cholinergic blocking drugs -is, 
however, variable (Table I), although the lack of 
inhibition of EIA in some studies may be due to 
insufficient cholinergic blockade (Tinkelman et al,
1976).
The purpose of this study was to investigate the 
effects of the anticholinergic drugs ipratropium 
bromide and atropine sulphate in the prevention of 
EIA.
METHODS
Nine patients with extrinsic asthma were studied 
(Table XXII). FEV^ was measured in triplicate using 
a dry wedge spirometer (Vitalograph), the best 
recording being used for analysis. Exercises were 
performed on an inclined treadmill as previously 
described. The study was completed within seven 
days.
After baseline measurements of FEV^, the following 
agents were administered by Wright nebuliser during 10 
min tidal breathing; Saline (9 g/1, 0.15 mol/1); 
ipratropium bromide (0.25 g/1, 0.6 mmol/1) - estimated
107
TA
BL
E 
XX
II
 
Cl
in
ic
al
 
de
ta
il
s 
of 
as
th
ma
ti
c 
pa
ti
en
ts
•H r
> Q) w
CM CO CMID in
10C'~ ro
coin co 00 I—1 
I—I
•H
incoinCM in co
coCM CM CM COCM CM
t?  Cn ■h ^ inID cr>ooCMin inini£> vo ID
CP £ invo00in CMID 00lO in in
rH
in
co
oo oo
rH CMCMCO CM
■H O 
■P 2
00incorH
dose nebulised 0.5 mg (1.2 pmol); atropine sulphate
(5 g/1, 7.1 mmol/1) - estimated dose nebulised 10 mg
After 20 min spirometry was repeated and then at 
5, 10 and 20 min after the exercise test. A positive 
response was defined as one in which there was a 
decrease in FEV^ of more than 20%. Saline and 
ipratropium bromide were given in a random single blind 
manner to all the patients, while atropine sulphate 
was given to only four patients (Nos 4, 5, 6, 9).
Statistical analysis was performed using "Student's 
paired t test.
RESULTS (Table XXIII, Figures 22, 23)
There was no significant difference between,the 
baseline values before aerosol administration on the 
two days. Ipratropium bromide produced a significant 
increase in FEV^ (P < 0.01) whereas there was no 
significant difference in FEV^ following saline. In 
the nine asthmatics studied ipratropium bromide had 
no protective effect on exercise-induced asthma when 
assessed as either the maximum absolute fall in FEV^ 
or the maximum percentage fall in FEV^. However, 
five (Nos 1, 2, 3, 7, 8) of the nine asthmatics studied 
developed less than a 15% fall in FEV^ after exercise 
following pre-treatment with ipratropium bromide, while 
all the subjects showed a greater than 20% fall in FEV^ 
after exercise following pre-treatment with saline.
No side effects were noted after the inhalation of
ipratropium bromide.
In the four asthmatics (Nos 4, 5, 6, 9) in whom 
a greater than 15% fall in FEV^ after exercise occurred 
following pretreatment with ipratropium bromide, atropine 
sulphate also did not inhibit EIA. All subjects 
experienced a dry mouth following the inhalation of 
atropine sulphate.
Detailed results for each patient are tabulated 
in Appendix D, Table LXVI.
DISCUSSION
The dose of atropine sulphate required in animals 
to block bronchoconstriction induced by stimulation of 
the vagi is between 0.5 mg/Kg to 2.0 mg/Kg body weight, 
which is higher than could be safely given to humans 
(Widdicombe & Stirling, 1970). Tinkelman et al, (1976) 
have suggested that the variable effect of anticholinergic 
drugs in preventing EIA could be due to insufficient 
cholinergic blockade. These authors reported that 
pre-treatment with 0.1 mg/Kg body weight of inhaled 
atropine sulphate prevented EIA in 17 out of 18 
asthmatic patients. Unfortunately, in that study 
the percentage fall- in spirometric measurements after 
exercise was calculated from the pre-treatment value, 
and not from the higher value following the 
bronchodilation produced by atropine sulphate. In 
the present study, the failure of high dose atropine 
sulphate (approximate dose 0.15 mg/Kg body weight) or
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ipratropium bromide to prevent EIA in four asthmatic 
patients, despite causing bronchodilation, suggests 
that in these patients cholinergic mechanisms are 
unlikely to have been important in the pathogenesis 
of EIA. However, the inhibitory effect of an even 
higher concentration of atropine on EIA cannot be 
completely excluded. The partial reduction of EIA 
with ipratropium bromide in the other five patients 
may indicate that vagal mechanisms are important in 
these subjects, or alternatively, the bronchodilation 
from ipratropium bromide may have resulted in reduced 
bronchial reactivity, due to a change in baseline 
airflow obstruction (Benson, 1975).
It is concluded that the lack of inhibition of 
EIA in some patients following anticholinergic drugs 
is probably not due to insufficient cholinergic 
blockade. This may indicate that mechanisms other 
than reflex vagal bronchoconstriction are involved 
in the pathogenesis of EIA.
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FIGURE 22 EFFECT OF EXERCISE ON MAXIMUM PERCENTAGE 
FALL IN FEV1 AFTER EXERCISE (MEAN - SEM) 
FOLLOWING IPRATROPIUM OR SALINE IN 
ASTHMATIC PATIENTS (N = 9)
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FIGURE 23 EFFECT OF EXERCISE ON MAXIMUM PERCENTAGE FALL 
IN FEV1 AFTER EXERCISE (MEAN - SEM) FOLLOWING 
IPRATROPIUM, ATROPINE OR SALINE IN ASTHMATIC 
PATIENTS (N = 4)
CHAPTER VII
EFFECT OF SODIUM CROMOGLYCATE AND 
IPRATROPIUM BROMIDE IN PREVENTION
OF EXERCISE-INDUCED ASTHMA
INTRODUCTION
Although the mechanisms involved in exercise- 
induced asthma (EIA) are unknown, both the release of 
bronchoconstrictor mediators (Godfrey, 1975) and reflex 
bronchoconstriction secondary to stimulation of vagal 
receptors (Gold, 1975) have been postulated. Sodium 
cromoglycate (SCG), which inhibits the release of 
mediators from mast cells (Orr et al, 1970), may have 
a preventive effect in EIA through a similar machanism 
(Davies, 1968). Circumstantial evidence supporting 
the hypothesis that reflex vagal bronchoconstriction 
is implicated in the pathogenesis of EIA is based on 
the inhibitory effects of anticholinergic drugs. However, 
the results of the previous experiment (Chapter VI) 
suggest that the lack of inhibition of EIA in some 
patients following anticholinergic drugs is unlikely 
to be due to insufficient cholinergic blockade. In 
an uncontrolled study reported by McFadden et al,
(1977 ) the combination of SCG and the anticholinergic
drug ipratropium bromide (IB) inhibited EIA in all 
patients studied, whereas IB alone inhibited only those 
patients with mainly large airways obstruction as 
assessed by changes in density dependence of maximal 
expiratory flow rates. SCG was not given alone.
They concluded that the airway response to exercise 
in asthmatics is heterogeneous in terms of predominant 
site of flow limitation and with regard to mechanism.
The purpose of this study was, therefore, to
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investigate in a double blind manner the effects of SCG, 
IB and IB plus SCG in the prevention of EIA in patients 
whose main site of airflow obstruction was in small and 
large airways as assessed by maximal expiratory flow 
rate response to low density gas breathing. It was 
hoped that these results might further define the role 
of mediator release and vagal action in EIA.
METHODS
Thirteen patients with extrinsic asthma were 
studied (Table XXIV). FEV^ FVC and MMEF were 
measured in triplicate using a water-sealed spirometer 
(Godart), the best recording being used for analysis. 
MEFV curves were produced with the patient breathing 
air, and then an He-O^ mixture as previously described. 
Predicted normal values were taken from Cotes (1975) 
for FEV^ and FVC and from Cherniak & Raber (1972) 
for MMEF. Exercises were performed on an inclined 
treadmill as previously described. The four exercise 
tests performed on each patient were all completed 
within 10 days.
The studies were carried out in a random double­
blind fashion using the following agents administered 
by a Wright nebuliser during 10 min tidal breathing:
(1) SCG nebuliser solution (10 g/1, 19.5 mmol/1) - 
estimated dose nebulised 20 mg (39.0 jiinol) ; (2) IB
(1 g/1, 2.4 mmol/1) - estimated dose nebulised 2.0 mg 
(4.8 jpmol); (3) SCG (10 g/1, 19.5 mmol/1) + IB (1 g/1,
2.4 mrnol/1) solutions; and (4) saline solution (9 g/1, 
0.15 mol/1). Following baseline measurements of FEV,
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FVC/ MMEF and MEFV curves breathing air and He-C^/ the 
drug solution was inhaled for two periods of five 
minutes separated by an interval of one minute. After 
20 minutes spirometry was repeated, and then at 2, 5,
10/ 15 and 20 min after the exercise test. In three 
patients (Nos 4, 8, 10) MEFV curves breathing air and 
He-02 were also recorded between 5 and 10 min post 
exercise. A positive response was defined as one in 
which there was a decrease in FEV^ of more than 20%. 
Results of exercise tests were expressed as the maximum 
percentage and absolute fall in lung function after 
exercise compared to the post-drug or placebo baseline.
Statistical analysis was performed using "Student's 
paired and.unpaired t tests.
RESULTS
In eight of the 13 patients studied/ the mean
baseline ratio VC^TT /Vc^___ was over 1.20, and these50He 50AIR
were called responders; the remaining five patients 
were called non-responders (Table XXV). Hereafter, 
the results are referred to in these two groups.
The results of the tests are given in Tables 
XXVI, XXVII, XXVIII and Figures 24, 25, 26.
There was no significant difference between the 
baseline values of FEV^, FVC and MMEF before aerosol 
administration on the four days. Mean baseline MMEF 
was significantly lower in non-responders (P < 0.02),
but there were no significant differences in FEV^ or 
FVC. There was no differences between the falls in 
ventilatory capacity after the control exercise in 
the two groups.
SCG, IB and IB plus SCG all significantly 
inhibited the percentage and absolute fall in FEV^ 
after exercise in the responders. IB, however, had 
no protective action in the non-responders, unlike 
both SCG and IB plus SCG. IB had no significant 
effect on FVC after exercise in the non-responders.
SCG significantly prevented the percentage and absolute 
fall in MMEF in both responders and non-responders 
(percentage fall only), while IB had no protective 
action in either group. In responders the drugs 
shown to have a significant inhibitory action were 
equally effective in preventing the fall in FEV^ 
and MMEF. In addition, there was no difference 
between SCG and SCG plus IB in the non-responders.
In the three patients (Nos 4, 8, 10) in whom 
• #
^SOHe^SOAIR was measure<  ^after exercise, the ratio 
increased in one from 1.29 to 1.35(No 4), in another 
it fell from 1.57 to 1.00 (No 8), while in the third 
it remained 1.00 (No 10). These post-exercise values 
all refer to post IB exercise.
No side effects were noted during the study after 
any of the drugs used.
Detailed results for each patient are tabulated in 
Appendix D, Tables LXVI - LXXVII.
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DISCUSSION
Patients with asthma have been separated into two 
groups by measuring the MMEF rate response to low density 
gas breathing (Despas, Leroux & Macklem, 1972). Those 
showing an increase in flow rates on breathing helium 
are thought to have the major site of resistance to 
expiratory flow in the large central airways (classified 
responders), while in those showing no such increase, 
the major site is in the small peripheral airways 
(classified non-responders). Other factors affecting 
the major site of obstruction may be cigarette smoking 
and the presence of chronic bronchitis or recurrent 
respiratory infections (Antic & Macklem, 1976). Using 
this classification, eight patients in our study were 
responders while five were non-responders. The 
predicted baseline values of FEV^ and FVC did not 
differ between the two groups. Non-responders had, 
however, significantly lower flow rates in small airways 
as assessed by baseline MMEF rates (McFadden & Linden, 
1972).
In this study both SCG alone and in combination 
with IB inhibited EIA, as measured by fall in FEV^, in 
both responders and non-responders, while IB had a 
preventive action only in responders. IB had no 
inhibitory activity, however, in either responders or 
non-responders when assessed by the change in MMEF, 
while SCG was significantly inhibitory in both these . 
groups. If MMEF is a test of small airways calibre 
(McFadden & Linden, 1972) then IB unlike SCG would appear
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to have no inhibitory action on these airways. In both 
responders and non-responders there was no difference in 
the effectiveness of the drugs shown to have a preventive 
action in EIA. SCG, although given in nebulised form 
which is likely to have increased its penetration into 
the lungs, was given in the dose normally used from a 
spinhaler. The present result, therefore, confirms its 
effect in EIA reported by others (Davies, 1968; Godfrey & 
Konig, 1976). The estimated dose of IB nebulised was 
2.0 mg which is 50 times the normal therapeutic dose. 
Higher doses of anticholinergic agents are probably no 
more effective in preventing EIA (Chapter VI). In 
previous studies comparing SCG and IB in extrinsic 
asthmatics, Chan-Yeung (1977) reported the prevention 
of EIA in three out of four patients by IB and all by 
SCG, while Godfrey & Konig (1976) prevented EIA in 
three out of seven patients with atropine methonitrate 
and six out of seven with SCG. These authors did not, 
however, identify any differences between their patients 
and the therapeutic responses observed.
McFadden et al, (1 9 7 7 ^)' studied 12 patients with
EIA who were all responders prior to exercise. IB 
inhibited those in whom density dependence increased 
after exercise indicating predominantly large airways 
obstruction but had no effect in those with predominantly 
small airways obstruction as assessed by a decrease in 
density dependence. This latter group, however, 
showed diminution in EIA by the addition of SCG.
Despite not giving SCG alone, they proposed that
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mediator release might serve to initiate reflex 
bronchoconstriction. In our study# post exercise 
density dependence was measured in two responders# one 
showing an increase and the other a decrease in the 
density dependence. The response to IB in these two 
patients was similar to that predicted by McFadden
/ T_ \
et al# (1977 ). The non-responder prior to
exercise remained so after exercise as has been found 
by others (Chan Yeung et al# 1976).
The results of this study are in keeping with IB 
acting mainly in the large airways and SCG acting in 
both small and large airways. In addition# SCG by 
nebuliser appears to be equally effective in both 
responders and non-responders. The relevance of these 
findings in relation to the pathogenesis of EIA depends 
on the mode of action of SCG and IB. SCG is thought 
to act by temporarily stabilizing the mast cell and 
so preventing mediator release (Orr et al# 1970).
More recently, using a canine model of reflex 
bronchoconstriction, Jackson & Richards (1977) suggested 
that SCG may also reduce the activity of lung irritant 
receptors. This latter mode of action has not, however# 
been demonstrated in humans (Chapter V). IB could act 
on mast cells preventing mediator release (Kaliner,
Orange & Austen, 1972) although this seems unlikely since 
SCG was effective in patients in whom IB was not. IB 
could also be acting directly on smooth muscle cholinergic 
receptors which might implicate reflex vagal 
bronchoconstriction, or direct cholinergic stimulation.
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In addition# the bronchodilation from IB might result 
in reduced bronchial reactivity# due to a change in 
baseline airflow obstruction (Benson, 1975), although 
in this study an increase in airways calibre following 
IB occurred in both responders and non-responders.
A possible interpretation of the findings in this study 
is that mediator release is important in most extrinsic 
asthmatics with EIA. In those in whom the main site 
of airflow obstruction is in the large central airways, 
which are predominantly under vagal control, mediator 
release results in bronchoconstriction due to 
cholinergic mechanisms and direct smooth muscle action. 
When the main site of airflow obstruction is in the 
smaller airways under lesser vagal control, mediator 
release causes bronchoconstriction due to its direct 
action on smooth muscle, cholinergic activity being of 
little importance to overall airways calibre. In 
support of this hypothesis, the vagus nerve 
predominantly effects bronchomotor tone in the large 
airways (Vincent et al, 1970; Simonsson, 1972) and 
atropine has proportionally greater activity in these 
airways (Cavenaugh & Cooper, 1976; Ingram et al, 1977) . 
Unfortunately the bronchoconstrictor action of the local 
anaesthetic bupivacaine in asthmatics (Chapter V) 
prevented its use in further definina the vaaal 
component of EIA. It would appear, however, that this 
proposed mechanism may not be relevant in all patients, 
as two patients in this study were not inhibited by any 
of the drugs used.
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CHAPTER VIII
EFFECT OF AN ORAL CHROMONE FPL57787 IN 
PREVENTION OF EXERCISE-INDUCED ASTHMA
INTRODUCTION
Inhaled sodium cromoglycate prevents exercise- 
induced asthma (EIA) (Davies# 1968) # but is inactive 
after oral administration due to poor gastrointestinal 
absorption. A new oral chromone, FPL57787, has 
anti-allergic activity similar to that of sodium 
cromoglycate (Augstein et al, 1977) and is also 
well absorbed from the gut.
The purpose of this study was to investigate the 
effect of oral FPL57787 in preventing EIA.
METHODS
Ten patients with extrinsic asthma were studied 
(Table XXIX). FEV^, FVC and MMEF were measured in 
triplicate using a water-sealed spirometer (Godart), 
the best recording being used for analysis. Predicted 
normal values were taken from Cotes (1975) for FEV^ 
and FVC and from Cherniak & Raber (1972) for MMEF. 
Exercises were performed on an inclined treadmill.
The two exercise tests performed on each patient were 
completed within 10 days.
The preparations were given as eight tablets 
(FPL57787 12 mg and placebo) in a cachet to preserve 
blindness and the order of treatment was randomly 
assigned to each patient. Each cachet was taken 
with a draught of water on an empty stomach i.e. at 
least 30 min before a meal and not less than four hours 
after a previous meal. Lung function measurements
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were made pre-treatment, two hours post-treatment i.e. 
immediately before exercise and at 2, 5, 10, 15 and 20 
min after the exercise had been completed. Results 
were expressed as the maximum percentage and absolute 
fall in lung function after exercise compared to the 
two hours post-treatment value.
Statistical analysis was performed using "Student's" 
paired t test.
RESULTS
The results of the tests are given in Tables 
XXX, XXI, XXXII, and Figures 27, 28, 29. No significant 
difference in pre- or two hour post-treatment values of 
FEV^, FVC and MMEF was seen between the two study days. 
FPL57787 gave significant protection (P < 0.01) 
compared to placebo from the maximum percentage fall 
and maximum absolute fall in FEV^, FVC and MMEF after 
exercise. Following FPL57787, seven out of ten 
patients had less than a 20% fall in FEV^ after 
exercise, whereas following placebo all patients had 
greater than a 20% fall in FEV^ after exercise.
When compared to placebo, FPL57787 produced a small 
but significant percentage increase in FEV^ two hour 
after the drug (P < 0.01): (mean - ISD) Post FPL57787
10.0 - 10.8; post placebo 2.6 - 7.7. No significant 
increase was seen in FVC (post FPL57787 2.1 - 5.6; 
post placebo 1.3 - 3.7) or in MMEF (post FPL57787 
16.3 - 23.5; post placebo 15.6 - 18.9).
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FIGURE 27 EFFECT OF EXERCISE ON MAXIMUM PERCENTAGE 
FALL IN FEV1 AFTER EXERCISE (MEAN - SEM) 
FOLLOWING FPL57787 OR PLACEBO IN 
ASTHMATIC PATIENTS (N = 10)
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FIGURE 29 EFFECT OF EXERCISE ON MAXIMUM PERCENTAGE 
FALL IN MMEF AFTER EXERCISE (MEAN - SEM) 
FOLLOWING FPL57787 OR PLACEBO IN 
ASTHMATIC PATIENTS (N = 10)
Detailed results for each patient are tabulated 
in Appendix D, Tables LXXVIII - LXXX.
DISCUSSION
Both FPL57787 and sodium cromoglycate would appear 
to inhibit antigen-induced release of pharmacological 
mediators by stabilization of mast cell membranes 
(Orr et al, 1970; Augstein et al, 1977). In 
addition, FPL57787, unlike sodium cromoglycate, may also 
inhibit degranulation of basophils (Augstein et al, 1977). 
Recently, resulting from experiments with a canine model 
of reflex bronchoconstriction, Jackson & Richards (1977) 
suggested that sodium cromoglycate may have a blocking 
action on lung irritant receptors. It is possible, 
therefore, that a derivative of sodium cromoglycate. 
such as FPL57787, may have similar properties. However, 
in humans a blocking action of sodium cromoglycate on 
irritant receptors has yet to be demonstrated (Chapter 
V). If the principal effect of FPL57787 in man is 
the inhibition of mast cell degranulation, then the 
result of this study supports the hypothesis that 
exercise in asthmatic patients provokes mediator 
release (Godfrey, 1975; Chapter VII). The small 
improvement in pre-exercise lung function after 
FPL57787 compared to after placebo is unlikely to have 
been sufficient to account for its protective action, 
since the two hour post-treatment values of FEV^,
FVC and MMEF between the two study days were not 
significantly different. The apparent slight 
bronchodilation produced by FPL57787 in this study is
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unexplained, but was also noted in a pilot study on 
four asthmatic patients given 24 mg of FPL57787.
A drug shown to be effective in preventing 
exercise-induced asthma in the laboratory may not be 
clinically useful. The effectiveness of FPL57787 
in the long term prophylaxis of asthma is under 
study.
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CHAPTER IX
EFFECT OF ^  RECEPTOR AND H2 RECEPTOR 
ANTAGONISTS IN PREVENTION OF
EXERCISE-INDUCED ASTHMA
INTRODUCTION
Mediators of immediate hypersensitivity including 
histamine are released when sensitized human lung 
tissue interacts with specific antigen in vitro 
(Austen & Orange, 1975). It has been suggested that 
exercise challenge in asthmatics may also provoke 
mediator release (Godfrey, 1975). This hypothesis 
is supported by the finding that sodium cromoglycate 
and FPL57787, which inhibit the release of type I 
mediators from mast cells (Orr et al, 1970; Augstein 
et al, 1977)f may prevent exercise-induced asthma (EIA) 
through a similar mechanism (Davies, 1968; Godfrey & 
Konig, 1968; McFadden et al, 1 9 7 7  ^ ;  Chapters VII 
and VIII). In addition, raised arterial plasma 
histamine levels have been found after exercise in 
some studies (Ferris et al, 1978) although this has 
not been confirmed by others (Harries, O'Brien &
Burge, 1979).
The purpose of this study was to investigate the 
effects of H^ and H  ^receptor antagonists in the 
prevention of EIA. It was hoped that this might 
help define the role, if any, of histamine in EIA.
METHODS
Ten patients with extrinsic asthma were studied 
(Table XXXIII). FEV1, FVC and MMEF were measured in 
triplicate using a water-sealed spirometer (Godart), 
the best recording being used for analysis. Predicted
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normal values were taken from Cotes (1975) for FEV^ 
and FVC and from Cherniak and Raber (1972) for MMEF. 
Exercises were performed on an inclined treadmill.
The three exercise tests performed on each patient 
were all completed within 10 days.
The studies were carried out in a random double­
blind fashion using the following agents administered 
by a Wright nebuliser during 5 min tidal breathing:
(1) clemastine (0.5 g/1/ 1.0 mmol/1) - estimated dose 
nebulised 0.5 mg; (2) cimetidine (100 g/1, 0.39 mol/1) - 
estimated dose nebulised 100 mg; (3) saline solution 
(9 g/1, 0.15 mol/1). Following baseline measurements 
of FEV^, FVC and MMEF, the drug solution was inhaled 
for 5 min. After 30 min spirometry was repeated, and 
then at 2, 5, 10, 15 and 20 min after the exercise 
test. A positive response was defined as one in 
which there was a decrease in FEV^ of more than 20%. 
Results of exercise tests were expressed as the maximum 
percentage and absolute fall in lung function after 
exercise compared to the post-drug or placebo baseline. 
Statistical analysis was performed using "Student's" 
paired t test.
RESULTS
The results of the tests are given in Tables 
XXXIV, XXXV, XXXVI and Figures 30, 31, 32. No 
significant difference in pre- or 30 min post-treatment 
values of FEV^, FVC and MMEF was seen between the three
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study days. Cimetidine but not clemastine gave 
significant protection (P < 0.01) compared to placebo 
from the maximum percentage fall and maximum absolute 
fall in FEV^ and MMEF after exercise. There was no 
significant difference in values of FEV^, FVC and 
MMEF after exercise following pre-treatment with 
clemastine or cimetidine. No side effects were noted 
after either clemastine or cimetidine.
Detailed results for each patient are tabulated 
in Appendix D', Tables LXXXI - LXXXIX.
DISCUSSION
Bronchial lumen mast cells have been demonstrated 
in animals (Patterson et al, 1974) and man (Patterson 
et al, 1977; Ts'ao et al, 1977), and transfer of these 
cells from rhesus monkeys with airway reactivity to 
ascaris antigen has been reported to result in 
transient airway reactivity in recipient animals 
(Patterson et al, 1978). Furthermore, sensitized 
mast cells have been shown to release mediators by 
non-immunological mechanisms (Vane, 1971; Seale & 
Piper, 1978). It has been suggested, therefore, that 
in patients with asthma exercise may provoke chemical 
mediator release from sensitized mast cells (Godfrey, 
1975), possibly as a result of airways cooling during 
exercise (McFadden & Ingram, 1979).
The reduction in the immediate bronchial response 
to inhaled antigen following pre-treatment with
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antagonists (Nakazawa et al, 1976; Eiser et al, 1978^^) 
and the finding of raised histamine levels after 
antigen-induced bronchoconstriction (Bhat et al, 1977) 
suggests that histamine may be one of the chemical 
mediators released from mast cells following antigen 
challenge. The effect of receptor antagonists in 
EIA has previously been examined in a few patients.
No significant protection against EIA was found with 
parenteral mepyramine maleate (50 mg) in 5 asthmatics 
(McNeill et al, 1966), or with oral chorpheniramine 
(4 mg) in 2 asthmatics (Bianco et al/ 1974). The 
present results confirm these observations in a 
larger number of patients studied in a double-blind 
fashion. The failure of the receptor antagonist 
clemastine to inhibit EIA may be due to a number of 
factors. The dose of clemastine might have been 
insufficient to block local tissue levels of released 
histamine following exercise, although the dose of 
clemastine used in this study has been previously 
shown to reduce histamine induced bronchoconstriction 
in asthmatics (Chapter III). In addition, the 
deposition of the aerosol of clemastine to the 
receptors in the smaller airways, and hence the 
degree of receptor blockade may have been much 
less than in the larger central airways. If, however, 
the dose and method of administration of clemastine 
was sufficient to produce adequate receptor blockade, 
then these results suggest that either the release of 
chemical mediators from mast cells is not important 
in the pathogenesis of EIA or a mediator other than
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histamine such as SRS-A is of more relevance. The 
main evidence for chemical mediator release from mast 
cells occurring following EIA is dependent upon the 
inhibitory action of sodium cromoglycate (Davies, 1968; 
Chapter VII) and FPL57787 (Chapter VIII) in EIA being 
due to these drugs reducing the release of 
pharmacological mediators by the stabilization of 
mast cell membranes (Orr et al, 1970; Augstein et al, 
1977). Other postulated modes of action of sodium 
cromoglycate (and FPL57787) have yet to be demonstrated 
in man, and this has already been discussed (Chapters 
V, VII, VIII). Thus if these drugs action in EIA 
indicates mediator release, then another mediator 
such as SRS-A may be more important than histamine.
In support of this, diethylcarbamazine, which has been 
shown to inhibit release of SRS-A in the rat (Orange 
et al, 1968) and SRS-A and histamine from passively 
sensitized monkey lung tissue following antigen 
challenge (Ishizaka et al, 1971), has been found to 
protect against EIA in 15 out of 20 asthmatic 
children (Sly &. Matzen, 1974).
The main site of action of histamine on the 
airways of asthmatics is probably by a direct effect 
on bronchial smooth muscle receptors, rather than
H2 receptors (Chapter III). The partial reduction in
EIA with cimetidine, at a dose and by a method of 
administration which has been shown to have no effect 
on histamine induced bronchoconstriction, suggests 
that cimetidine may be preventing EIA by a mode of
127
action other than by blocking receptors. 
receptor antagonists induce catecholamine release 
(Owen, 1977), inhibit the metabolism of histamine 
(Thomas, Bochner & Lichtenstein, 1978) and induce 
histidine decarboxylase (Maudsley et al, 1973).
Of these effects only the release of catecholamines 
would reduce immediate hypersensitivity reactions and 
therefore possibly be relevant to the inhibition of 
EIA. Whether cimetidine is acting in this manner or 
by some other means remains to be elucidated.
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APPENDICES
APPENDIX A
. DEFINITION OF ASTHMA
There is no generally accepted definition of 
asthma (Ciba Foundation Study Group No. 38, 1971). 
Scadding (1977) has suggested asthma be considered 
as "a disease characterised by wide variations over 
short periods of time in resistance to flow in 
intrapulmonary airways", and proposed the following 
categories
(a) Extrinsic atopic asthma due to IgE-mediated 
hypersensitivity reactions in inhaled antigens 
commonly present in the air. Often presents 
with wheezy breathlessness early in life. 
Extrinsic implies that asthma is precipitated 
by contact with environmental antigens and 
atopic refers to the type of hypersensitivity 
reaction involved. The asthmatic patients 
investigated in this study would be included in 
this category.
(b) Extrinsic non-atopic asthma due to reactions 
between inhaled antigens and antibodies other 
than IgE.
(c) Intrinsic asthma usually begins later in life, 
tends to be persistant.and have a non-seasonal
129
incidence. The serum total IgE is not 
elevated but a blood eosinophilia may be 
present.
(d) Exercise-induced asthma may be present in both 
extrinsic and intrinsic types.
(e) Asthma associated with chronic broncho-pulmonary 
disease.
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APPENDIX B
DERIVATION OE PHYSIOLOGICAL MEASUREMENTS
Body Plethysmography
According to Poiseuille's equation:
8 1^
Resistance =
Where 1 is the length of tube (airway), r is the 
radius of the tube, and is the viscosity of the 
gas. This equation may not be strictly applicable 
to the airways, but it can be accepted that large 
changes in resistance occur with relatively small 
changes in airway calibre (Pride, 1971). Consequently, 
the measurement of airways resistance is a very 
sensitive indirect way of detecting small changes 
in the size of the airways.
In 1956 a method for measuring airways resistance 
using a constant volume type of whole-body 
plethysmograph was introduced (DuBois et al, 1956^  ; 
DuBois, Botelho & Comroe, 1 9 5 6  ^ ) .  The subject 
breathes into the box which is closed, and of constant 
volume. There is an inverse relationship between 
alveolar and box pressure. The subject pants gently 
against a closed shutter which occludes flow, and 
pressures are measured simultaneously in the box and 
at the mouth. Since no flow is occurring, mouth
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pressure will be the same as alveolar pressure. From 
this procedure a relationship is obtained between 
alveolar pressure and box pressure: A  P^/ A.Pgox
With the shutter open and the subject breathing 
gently, a relationship between flow and box pressure 
is obtained V/ ^ pBox* From these relationships, 
airways resistance is obtained as follows:
^  PA ^  PBox
Airway resistance = ------- x
^  PBox
In addition, thoracic gas volume can be derived 
when the subject pants against the closed shutter.
The lung volume increases, Av, the alveolar pressure 
falls by an amount and box pressure rises by an
amount PBox- From Boyles law, which states that 
the product of pressure and volume is constant 
(at constant temperature), the thoracic gas volume 
is obtained.
Thoracic gas volume =
A V ( pb)
A p ,A
(PB is barometric pressure)
Flow-volume Curves
Maximal expiratory flow is determined by the 
static recoil pressure of the lungs and resistance of 
the upstream segment (i.e. from alveolus to equal 
pressure point (EPP) (Mead et al, 1967). Since 
static record pressure of the lungs does not change 
with helium (He), (Despas et al, 1972), increases in
132
t
expiratory flow at 50% vital capacity (V^Q) with He 
are thought to result from a decrease in the resistance 
of the upstream segment. The resistance of the 
upstream segment is made up of convective 
acceleration, frictional resistance to laminar flow 
and frictional resistance to turbulent flow. Resistance 
to convective acceleration is dependent upon gas density 
(P) and is inversely related to the square of the 
cross-sectional area of EPP.
VPD
Reynold's number = ---
2f
Where V = linear velocity and equals flow divided 
by total airway cross-sectional area,
P = gas density
D = airway diameter
y  = gas viscosity
In the peripheral airways, flow is probably 
laminar, where the total cross-sectional area is large, 
and linear velocity is low, resulting in a low 
Reynold's number. Resistance to laminar flow is 
independent of gas density, but is directly related 
to gas viscosity (Poiseuille1s equation). Turbulent 
flow occurs in airways with higher Reynold's numbers, 
resistance then becoming density dependent. Therefore, 
subjects showing an increase in flow rates on breathing 
He are thought to have the major site of resistance to
133
expiratory flow in the large central airways 
(responders) where in those showing no such increase 
the major site is thought to be in the small peripheral 
airways (non-responders).
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APPENDIX C
EFFECT OF INHALED PLACEBO IN THE PREVENTION OF 
EXERCISE-INDUCED ASTHMA
Ten patients with extrinsic asthma were studied 
(Table XXXVII). FEV^ was measured in triplicate 
using a water-sealed spirometer (Godart), the best 
recording being used for analysis. Exercises 
were performed on an inclined treadmill and the study 
was completed within ten days.
After baseline measurements of FEV^, the 
following agents were administered by Wright nebuliser 
during 10 min of tidal breathing: placebo one
(saline, 9 g/1, 0.15 mmol/1); placebo two (saline,
9 g/1, 0.15 mmol/1). After 30 min, spirometry was 
repeated and then at 2, 5, 10, 15 and 20 min after 
the exercise test. Placebo one and two were given 
in a random double-blind manner. Statistical 
analysis was performed using "Student's" paired t 
test.
Results (Tables XXXVIII, XXXIX, Figure 4 )
The baseline values of FEV^ before and after 
aerosol administration on the two days were similar 
(P > 0.05). There was no significant difference in 
the effect of pre-treatment with placebo one or two 
in preventing the fall in FEV-^  after exercise 
(t = 0.44; P > 0.30).
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TABLE XXXIX Effect of exercise on FEV  ^ following
placebo 1 and 2 in asthmatic patients 
(N = 10)
Patient Baseline Absolute values for FEV^ after
exercise
No B A 2min 5min lOmin 15min 20min
PLACEBO 1
1 3.18 3.20 3.11 2.76 2.35 2.53 2.69
2 4.50 4.75 4.52 3.53 3.15 3.78 3.95
3 2.98 2.97 2.24 2.19 2.25 2.43 2.75
4 3.64 3.64 3.34 3.18 2.91 3.03 3.43
5 4.32 4.30 4.12 3.65 3.35 3.54 3.75
6 2.71 3.09 2.38 1.88 2.04 2.54 2.51
7 2.55 2.58 1.99 2.00 1.75 1.67 1.74
8 4.95 4.96 4.15 3.21 2.28 2.95 3.78
9 3.75 3.73 2.85 2.56 2.75 3.05 3.48
10 4.55 4.55 4.10 3.65 3.34 3.67 3.96
Mean 3.71 3.78 3.28 2.86 2.62 2.92 3.20
SEM 0.27 0.26 0.29 0.21 0.18 0.21 0.23
PLACEBO 2
1 3.31 3.38 3.21 2.54 2.38 2.98 3.25
2 4.45 4.65 3.55 3.50 3.48 3.41 3.65
3 3.08 3.18 2.53 1.93 1.77 2.32 2.67
4 3.88 3.88 3.65 3.25 3.00 3. 35 3.58
5 4.02 4.05 3.72 3.15 3.03 3.25 3.48
6 2.41 2.58 1.64 1.61 1.56 1.74 1.94
7 2.59 2.53 2.18 1.62 1.67 1.77 1.64
8 4.85 4.93 3.88 2.86 2.76 2.85 3.30
9 3.71 3.79 2.95 2.71 2.79 2.95 3.53
10 4.49 4.53 4.05 3.51 3.19 3.43 3.83
Mean 3.68 3.75 3.14 2.67 2.56 2.80 3.09
SEM 0. 26 0.26 0.25 0.23 0.22 0.20 0.24
APPENDIX D 
ADDITIONAL TABLES
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